The effect of soy protein beverages on serum cell adhesion molecule concentrations in prehypertensive/stage 1 hypertensive individuals by Dettmer, Michelle Elise
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2011
The effect of soy protein beverages on serum cell
adhesion molecule concentrations in
prehypertensive/stage 1 hypertensive individuals
Michelle Elise Dettmer
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Nutrition Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Dettmer, Michelle Elise, "The effect of soy protein beverages on serum cell adhesion molecule concentrations in prehypertensive/stage
1 hypertensive individuals" (2011). Graduate Theses and Dissertations. 11995.
https://lib.dr.iastate.edu/etd/11995
  
The effect of soy protein beverages on serum cell adhesion molecule 
concentrations in prehypertensive/stage 1 hypertensive individuals 
 
 
by 
 
 
Michelle Elise Dettmer 
 
 
A thesis submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
MASTERS OF SCIENCE 
 
Major: Diet and Exercise 
 
 
Program of Study Committee: 
D. Lee Alekel, Major Professor 
Warren Franke 
Alicia Carriquiry 
 
 
 
 
 
 
Iowa State University 
Ames, Iowa 
2011 
Copyright © Michelle Elise Dettmer, 2011. All rights reserved
 ii   
 
 
TABLE OF CONTENTS 
LIST OF TABLES           v 
LIST OF FIGURES          vi 
LIST OF ABBREVIATIONS         vii 
ABSTRACT           viii 
GENERAL INTRODUCTION   1 
 Thesis Organization         1 
 Objectives          1  
 Hypotheses          1 
 Specific Aims          1 
 Limitations          2  
 Significance and Strengths        3 
REVIEW OF LITERATURE         5 
 Relationship of Hypertension to Cardiovascular Disease     5 
 Risk Factors for Hypertension        6 
  Non-modifiable         6 
  Modifiable         7 
Inflammation          9  
 Leukocyte Adhesion Cascade       10 
  Cell Adhesion Molecules       12 
Endothelial-leukocyte Adhesion Molecule-1 (E-selectin-1)  12 
Vascular Cell Adhesion Molecule-1 (VCAM-1)    13 
   Intercellular Cell Adhesion Molecule-1 (ICAM-1)    13 
 Cell Adhesion Molecules, Inflammation, and Atherosclerosis    13 
  Inflammation and Atherosclerosis      13 
Factors Related to Adhesion Molecule Expression    14 
 iii   
 
 
 Age         14  
Gender 14 
Smoking         15 
Cancer and other diseases      15 
Obesity         15 
Diabetes         16 
Hyperlipidemia        16 
Hypertension        17 
Endothelial dysfunction       17 
Cardiovascular disease       18 
 Milk Intervention         19 
  Cow’s Milk         19 
  Blood pressure response      19 
  Cell adhesion molecule expression     21 
 Soy Products         22 
  Blood pressure response      22 
  Cell adhesion molecule expression     23 
Summary         25 
 References          27 
MANUSCRIPT 
Title:  The Effect of Soy Protein Beverages on Serum Cell Adhesion Molecule Concentrations in 
Prehypertensive/Stage 1 Hypertensive Individuals      42 
 Abstract          42 
 Key Words          43 
 Introduction          43 
 iv   
 
 
 Methods          45 
  Research Design        45 
  Subject Screening, Selection, and Characteristics    45 
  Subject Randomization and Treatment      46 
  Data Collection         46 
   Questionnaires and Dietary Intake Assessment    46 
   Body Size and Composition Assessment     47 
   Laboratory Measurements      47 
  Statistical Analyses        48 
 Results           48 
  Urinary Analyte Excretion and Compliance     49 
  Subject Characteristics and Dietary Intake     49  
  Serum Cell Adhesion Molecules       50 
 Discussion          50 
 Acknowledgements         55 
 References          55 
 Tables           59 
GENERAL CONCLUSIONS         67  
ACKNOWLEDGEMENTS          68 
 v   
 
 
LIST OF TABLES 
Table 1. Nutrient composition of treatment beverages      59  
Table 2. Urinary analyte excretion        60 
Table 3. Characteristics of participants at baseline      61 
Table 4. Energy and nutrient intake at baseline       64 
Table 5. Soluble endothelial adhesion molecules at baseline and after 8 weeks of treatment 
 beverage intake         66 
 vi   
 
 
 
LIST OF FIGURES 
Figure 1. Conceptual Model:  Factors related to increased expression of cell adhesion molecules  
and atherosclerotic cardiovascular disease      4 
Figure 2. Leukocyte Adhesion Cascade        12
 vii   
 
 
 
LIST OF ABBREVIATIONS 
Ang II  Angiotensin II 
CAM  Cell adhesion molecules 
CVD  Cardiovascular disease 
DBP  Diastolic blood pressure 
E-selectin Endothelial-leukocyte adhesion molecule 
HDL  High-density lipoprotein 
HTN  Hypertension 
ICAM-1  Intercellular adhesion molecule-1 
LDL  Low-density lipoprotein 
SBP  Systolic blood pressure 
SPI  Soy protein isolate 
VCAM-1 Vascular cell adhesion molecule-1 
WSB  Whole soy bean
 viii   
 
 
 
ABSTRACT 
Background and Aims:  Prehypertensive and hypertensive individuals are at an increased risk of 
atherosclerotic cardiovascular disease. The role of hypertension in endothelial dysfunction and 
increased cell adhesion molecule (CAM) expression may lead to atherosclerotic progression. Soy protein 
and isoflavones have been shown to favorably alter cardiovascular disease risk factors. The aim of this 
study was to determine the effect of daily cow’s milk compared with soy beverage prepared from whole 
soy bean (WSB) or soy protein isolate (SPI) on soluble cell adhesion molecules. 
Methods:  We enrolled healthy prehypertensive/Stage 1 hypertensive men (n=60, aged 18 – 63 yr) and 
premenopausal women (n=8, aged 20 – 48 yr) and randomized them to one of three beverage groups 
for 8 weeks of treatment:  cow’s milk (600 mL/d), soy beverage (840 mL/d) prepared from SPI (30.1 mg 
total isoflavones/d [aglycone form]) or prepared from WSB (91.4 mg total isoflavones/d [aglycone 
form]). We measured soluble vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion 
molecule-1 (ICAM-1), and endothelial-leukocyte adhesion molecule-1 (E-selectin) at baseline and week 
8. 
Results:  Treatment did not alter soluble CAM concentrations. Time had an effect on VCAM-1 (-9%, P = 
0.01) and E-selectin (+4%, P = 0.01) but not ICAM-1 (+5%, P=0.86). Gender also had a significant effect 
on ICAM-1 (P=0.0037), whereas gender did not reach significance for E-selectin (P=0.067) or VCAM-1 
(P=0.16). Men had higher circulating concentrations of ICAM-1 and E-selectin, respectively, at both 
baseline (P = 0.0071, P = 0.049) and week 8 (P = 0.0054, P = 0.038) than women. ICAM concentrations 
were not significantly different between prehypertensive and hypertensive participants. 
Conclusion:  Prehypertensive/Stage I hypertensive individuals who consumed either cow’s milk or soy 
beverages (prepared from WSB or SPI) for 8 weeks daily did not show any change in soluble CAM 
concentrations. Consequently, we cannot suggest that daily intake of either cow’s milk or soy protein 
beverages improves circulating CAM concentrations and hence risk of atherosclerotic CVD in these 
individuals. 
 
KEY WORDS:  Cardiovascular disease risk, Cell adhesion molecules, VCAM-1, ICAM-1, E-selectin, 
Isoflavones, Soy protein
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GENERAL INTRODUCTION 
Thesis Organization 
 The general introduction of this thesis describes the objectives, hypotheses, specific aims, 
limitations, and significance of this study. Figure 1 portrays the overall conceptual model of this study. 
Pertinent background information follows in the review of literature. 
Objectives 
 The long term objective of this research was to identify a clinical intervention for reducing 
subclinical inflammation, thereby decreasing risk of atherosclerotic cardiovascular disease (CVD). The 
primary objective of this study was to determine whether daily intake of soy protein beverage compared 
with cow’s milk, for eight weeks affected concentrations of inflammatory markers in 
prehypertensive/Stage I hypertensive individuals. The specific inflammatory markers of interest were 
cell adhesion molecules (CAM):  soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble 
intercellular adhesion molecule-1 (sICAM-1), and soluble endothelial-leukocyte adhesion molecule-1 (sE-
selectin). The secondary objective was to observe and compare the magnitude of change in CAM 
concentrations in response to each treatment and to determine whether gender differences were 
important. 
Hypotheses 
1. Daily intake of soy beverages (prepared from either whole soy bean [WSB] or soy protein isolate 
[SPI]) and cow’s milk for eight weeks will reduce inflammation, as evidenced by a decrease in 
serum sVCAM-1, sICAM-1, and/or sE-selectin, in prehypertensive/Stage I hypertensive 
individuals. 
2. The reduction of serum sVCAM-1, sICAM-1, and sE-selectin concentrations will be greater for 
individuals who consumed daily a soy protein beverage (prepared from either WSB or SPI) 
compared to those who consumed cow’s milk. 
3. Individuals who consumed the soy protein beverage prepared from WSB will experience a 
greater reduction of serum sVCAM-1, sICAM-1, and sE-selectin compared to individuals who 
consumed the soy protein beverage prepared from SPI. 
Specific Aims 
1. To determine change in VCAM-1, ICAM-1, and E-selectin markers of inflammation, as a function 
of eight weeks of soy beverage consumption compared with cow’s milk in 
prehypertensive/Stage 1 hypertensive individuals. 
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a. Serum sVCAM-1, sICAM-1, and sE-selectin were measured via enzyme-linked 
immunosorbent assay (ELISA) 
2. To determine whether soy protein beverage (prepared from either WSB or SPI) reduced sVCAM-
1, sICAM-1, sE-selectin concentrations to a greater extent than that of cow’s milk. 
3. To determine whether soy protein beverage prepared from WSB, as a function of its higher 
isoflavone content, reduced sVCAM-1, sICAM-1, sE-selectin concentrations to a greater extent 
than that of soy protein beverage prepared from SPI. 
a. Concentrations of isoflavones in the soy protein beverages were analyzed by HPLC 
(Beckman Coulter, Fullerton CA) at Iowa State University (Murphy et al. 1981). 
Limitations 
The purpose of this study was to determine whether CAM concentrations (indicative of 
inflammation), specifically VCAM-1, ICAM-1, and E-selectin, would be reduced in response to the intake 
of soy protein beverages (prepared from either WSB or SPI) compared to cow’s milk in 
prehypertensive/Stage I hypertensive individuals. The inclusion of men and premenopausal women in 
this study differed from previous research, in that most studies prior to this investigation included 
postmenopausal women exclusively. Despite our efforts to recruit men and premenopausal women, we 
did not include both sexes equally (60 men versus 8 women) because premenopausal women with 
hypertension (HTN) were very difficult to enroll, since they are relatively unusual. 
This investigation did not include a true placebo control group, although we included the cow’s 
milk group as a realistic control for the soy beverages. In essence, we were not able to determine the 
response to a true placebo control in prehypertensive/Stage I hypertensive individuals. However, we did 
not expect the same magnitude of response from the cow’s milk group. Consequently, we will discuss 
differences in CAM among the three treatment groups post-intervention and changes in CAM within 
each treatment group from baseline to post-intervention. 
This study was designed to examine changes in CAM as biomarkers of inflammation in an at-risk 
group:  prehypertensive/Stage I hypertensive individuals. However, it would be meaningful to compare 
CAM concentrations between normotensive and prehypertensive/Stage I hypertensive individuals. The 
inclusion of healthy, normotensive individuals would have provided a comparison of CAM values 
indicative of minimal inflammation. Because the funding agency specifically did not want us to include a 
group of normotensive individuals, this has somewhat limited the interpretation of our results. In this 
study, the statistical analyses focused on the differences in CAM among the three groups post-
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treatment, as well as the relative change in CAM from baseline to post-treatment within each group. In 
addition, previous studies examined primarily postmenopausal women, thereby limiting the availability 
of a reference range of CAM concentrations from healthy premenopausal women, a target demographic 
in our study. 
Significance and Strengths 
Hypertension is a leading risk factor for stroke, coronary heart disease, congestive heart failure 
(Kannel et al. 1969), peripheral vascular disease, and renal insufficiency (Burt et al. 1995; Chobanian et 
al. 2003; Stamler et al. 1993; Wang et al. 2005). In the US, 41% of non-Hispanic blacks and 22% of non-
Hispanic whites have HTN, many of whom are unaware of their condition (Ostchega et al. 2008). 
Hypertension is a major risk factor contributing to the pathogenesis of atherosclerotic CVD, the primary 
cause of death in the US, which is readily preventable and/or controllable (Lloyd-Jones et al. 2010). 
Uncomplicated HTN in men compared with normotensive men has been reported to result in 
elevated VCAM-1 and ICAM-1 concentrations (Chae et al. 2001; DeSousa et al. 1997). Although 
hypertensive patients may have elevated concentrations of VCAM-1, ICAM-1, and E-selectin compared 
to normotensive patients, these markers are significantly increased in both groups following an acute 
rise in blood pressure via a cold pressor test (Buemi et al. 1997). These findings demonstrate a potential 
role of essential and acute HTN in inflammation and endothelial cell function. However, elevated CAM 
has not been demonstrated consistently in prehypertensive individuals. 
The isoflavones, genistein, daidzein, and glycitein (and their respective glycosides), found in soy 
foods have anti-inflammatory properties (Chacko et al. 2005; Wei et al. 1995), but this has not been 
confirmed in uncomplicated HTN (prehypertension/Stage I HTN). Genistein has been shown to have a 
potent anti-inflammatory action via inhibiting monocyte adhesion to cytokine-activated endothelial cells 
(Chako et al. 2005). Isoflavones may also have cardioprotective properties similar to endogenous 
estrogen (Hall et al. 2005). What is not known is whether soy protein intake in prehypertensive/Stage I 
hypertensive men and premenopausal women not only may decrease blood pressure, but reduce 
VCAM-1, ICAM-1, and E-selectin concentrations to a greater extent than cow’s milk. Should we 
determine that soy consumption reduces VCAM-1, ICAM-1, and E-selectin in prehypertensive/Stage I 
hypertensive men and premenopausal women, this would provide evidence that this dietary 
intervention might decrease inflammation in individuals prior to manifestation of CVD, thereby reducing 
HTN-related risk of atherosclerotic CVD.
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Figure 1. Conceptual Model:  Factors related to increased expression of cell adhesion molecules and 
atherosclerotic CVD. NFκB, nuclear factor kappa B; NO, nitric oxide; ROS, reactive oxygen species; AGE, 
advanced glycation endproducts; BMI, body mass index; TNF-α, tumor necrosis factor α; ICAM-1, 
intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; E-selectin, endothelial-
leukocyte adhesion molecule-1; CVD, cardiovascular disease 
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Relationship of Hypertension to Cardiovascular Disease 
Hypertension (HTN) is a modifiable risk factor for CVD. Cardiovascular disease is the leading 
cause of death in the United States, accounting for over 50 percent of all deaths (Lloyd-Jones et al. 
2010). Hypertension is defined as a systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood 
pressure (DBP) ≥ 90 mmHg. Normal blood pressure is defined as a SBP < 120 and DBP < 80. 
Prehypertension is defined as a SBP 120-139 mmHg and/or a DBP 80-89 mmHg. The Framingham Heart 
Study has indicated that risk of CVD is more than doubled for individuals with SBP levels 130 to 139 
and/or DBP 85 to 89 mmHg compared to individuals with blood pressure levels less than 120/80 mmHg 
(Vasan et al. 2001). Observational studies that included more than 1 million people, ages 40 to 89, have 
associated increased death from ischemic heart disease and stroke with either elevated SBP levels ≥ 115 
mmHg and/or DBP levels ≥ 75 mmHg (Lewinton et al. 2002). It is estimated that for every 20 mmHg 
increase in SBP or 10 mmHg increase in DBP, mortality from ischemic heart disease and stroke is 
doubled (Chobanian et al. 2003). 
 Although HTN is a well recognized risk factor for CVD, the underlying mechanism related to the 
pathology of CVD is unknown. Hypertension may be a stimulus for inflammation (Kranzhöfer et al. 1999; 
Chae et al. 2001) and endothelial activation (Liu et al. 1996), implicating its role in atherogenesis (Ross 
1999). Increased blood pressure has been associated with significant increases in the concentration of C-
reactive protein (CRP) and interleukin-6 (IL-6), both markers of inflammation (Bermudez et al. 2002; 
Blake et al. 2003; Chae et al. 2001; Fernandez-Real et al. 2001). 
Angiotensin (Ang) II is a primary effector of the renin-angiotensin aldosterone system and a 
potent vasoconstrictor, playing a crucial role in the regulation of blood pressure (Ross 1999). In 
hypertensive patients, Ang II is often elevated. Elevated Ang II may contribute to the intimal 
inflammation evident in hypertensive individuals, as Ang II can stimulate IL-6 expression by smooth 
muscles cells (Kranzhöfer et al. 1999; Libby et al. 2002). Angiotensin II is also involved in the remodeling 
of the arterial wall (Matsusaka and Ichikawa 1997) and is known to stimulate oxidative stress in several 
cell types, including endothelial cells found on the interior surface of blood vessels (Pueyo et al. 1998). 
Oxidative stress contributes to endothelial damage via the inflammatory cells, polymorphonuclear 
leukocytes, which release reactive oxygen species (ROS) when activated (Smedly et al. 1986). 
Hypertensive individuals have been shown to have significantly increased polymorphonuclear leukocyte-
induced oxidative stress (Yasunari et al. 2002). The increase in oxidative stress in hypertensive 
individuals perpetuates the endothelial damage considered to be the first step in atherogenesis. 
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Risk Factors for Hypertension 
Hypertension afflicts an estimated 29 percent of adults in the United States, in addition to 37 
percent who have prehypertension (Ostchega et al. 2008). Untreated HTN increases the risk of heart 
attack, heart failure (Kannel et al. 1969), stroke, and kidney disease (Burt et al. 1995; Chobanian et al. 
2003; Stamler et al. 1993; Wang et al. 2005). The risk for these conditions may also be increased in 
individuals with prehypertension (Vasan et al. 2001), although the evidence is not as clear. The 
prevalence and grave consequences of this condition are alarming. Although HTN is related to an 
increased risk of CVD, HTN may be averted. Recent investigations have identified non-modifiable and 
modifiable risk factors for HTN as summarized herein. 
Non-modifiable 
Non-modifiable risk factors for HTN include age, gender, race, and genetics. In most populations 
SBP has been shown to rise disproportionately with advancing age compared to DBP. Both pressures 
increase with age into adulthood, yet DBP tends to peak in the sixth decade and then decline, while SBP 
continues to rise into elderly adulthood (Kannel and Gordon 1977). This disproportionate rise in SBP 
compared to DPB has been related to a progressive loss of arterial elasticity during the lifespan (Kannel 
and Gordon 1977). In women, longitudinal data suggest that DBP is parallel but persistently lower than 
men. However, SBP is initially lower in women and eventually converges with that of men near the age 
of 60. Gender differences in peripheral SBP have also been attributed to differences in body height. 
Systolic blood pressure amplification from the central to peripheral vasculature increases with height. 
Because women tend to be shorter than men, this amplification is less pronounced and peripheral SBP is 
lower in women (London et al. 1995). 
Differences in ethnicity have a pronounced impact on blood pressure. The US Department of 
Health and Human Services that conducts the National Health and Nutrition Examination Survey 
(NHANES) found that the non-Hispanic black population had the highest prevalence of HTN (41%), 
significantly higher than those of non-Hispanic white (28%) or Mexican-American (22%) populations 
(Ostchega et al. 2008). Non-Hispanic blacks have much higher mean blood pressure values and develop 
high blood pressure earlier in life compared to non-Hispanic whites (Lloyd-Jones et al. 2010). These 
differences in blood pressure have been attributed to heredity, the reduced ability to photosynthesize 
vitamin D3 based on skin melanin content (Rostand 1997), and psychosocial stressors (Kriger and Sidney 
1996). High blood pressure may be more prevalent in adult non-Hispanic black populations due to a 
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higher incidence of obesity (32%) compared to non-Hispanic white (24%) and Asian (9%) adult 
populations (Pleis and Lethbridge-Cejku 2006). 
Genetic regulation of blood pressure occurs in at least eight genome loci (Cheh et al. 2009) that 
may regulate blood pressure via variations in plasma angiotensinogen concentration (Kim et al. 1994) 
and renal sodium reabsorption (Lifton et al. 2001), among other yet identified mechanisms. The 
Framingham Heart Study examined related individuals and found that if measured once, blood pressure 
levels are almost 40% heritable, and when measured multiple times, blood pressure trends are nearly 
55% heritable (Levy et al. 2000). 
Modifiable 
Modifiable risk factors include excess body weight, physical inactivity, excess sodium intake, 
excess alcohol intake, diet, and caffeine consumption. Excess body weight and body mass index (BMI; 
kg/m2) are positively associated with blood pressure (Dyer et al. 1989). Screening of more than 1 million 
people revealed self-reported overweight individuals had HTN prevalence rates 50 to 300 percent higher 
than other individuals for each age-, sex-, and race-group (Stamler et al. 1978). The INTERSALT study 
associated a 10 kg difference in body weight with an average of 3.0 mmHg difference in SBP and 2.2 
mmHg difference in DBP (Dyer et al. 1989). Because of the strong relationship between body weight and 
blood pressure, weight loss is the primary objective in the prevention and treatment of HTN. It must be 
noted that although significant relationships between blood pressure and weight have been reported, 
these values fall within potential measurement error when assessing blood pressure. Thus, it is unclear 
whether or not these small differences are biologically important. Nevertheless, weight loss has been 
shown to reduce SBP and DBP in overweight hypertensive patients (Reisin et al. 1983), as well as in 
overweight patients with prehypertension (Stamler et al. 1989). A meta-analysis that included 25 trials 
reported that an average weight loss of 5.1 kg reduced SBP by 4.4 mmHg and DBP by 3.5 mmHg (Neter 
et al. 2003). Furthermore, greater weight loss is associated with greater blood pressure reduction 
(Huang et al. 1998; Stevens et al. 1993). 
Physical fitness is inversely related to SBP (Cooper et al. 1976). Clinical trials have demonstrated 
a reduction in blood pressure in hypertensive and normotensive subjects with physical activity, 
independent of weight loss (Arrol and Beaglehole 1992; Whelton et al. 2002). Whelton et al. (2002) 
conducted a meta-analysis with 54 randomized, controlled trials and concluded that aerobic exercise, 
performed at least 30 minutes most days of the week, significantly reduced mean SBP by 3.8 mmHg and 
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mean DBP by 2.6 mmHg. Because these declines approximate the measurement error of assessing blood 
pressure, they should be interpreted with caution. 
Dietary components most often related to the prevention and treatment of HTN include 
reduced sodium chloride (salt) and alcohol consumption. Several controlled, dose-response trials, 
testing at least three sodium levels, have found a statistically significant, direct, and progressive dose-
response relationship with blood pressure (Johnson et al. 2001; MacGregor et al. 1989; Sacks et al. 
2001). The well recognized Dietary Approaches to Stop Hypertension (DASH)-Sodium trial combined a 
diet high in fruits, vegetables, and low-fat dairy products with three sodium intakes (50, 100, and 150 
mmol/2,100 kcal; 1150 mg, 2300 mg, 3450 mg, respectively) and compared this diet to that of a typical 
American diet. Blood pressure reduction was direct and progressive in all subgroup categories (i.e., men, 
women, blacks, nonblacks), at all three sodium levels, and greatest when sodium intake was ≤100 
mmol/2100 kcal (2300 mg) (Bray et al. 2004). He and Mac Gregor (2002) compiled a meta-analysis 
documenting that a median reduction in urinary sodium ≈1800 mg/d (78 mmol/d) resulted in reduced 
SBP and DBP, respectively, by 5.0 and 2.7 mmHg in hypertensive individuals and by 2.0 and 1.0 mm Hg in 
non-hypertensive individuals. The values reported in the non-hypertensive individuals likely lack 
biological relevance as they fall within the measurement error of blood pressure. Recommendations 
from the American Heart Association (AHA) suggest reducing salt intake as much as possible, ideally to 
less than 3.8 g/d sodium (≈1500 mg/d) chloride  (Appel et al. 2008). Alcohol consumption, independent 
of age, obesity, and salt intake (Okubu et al. 2001), has been indicated to have a direct, dose-response 
relationship with blood pressure, especially when consumption exceeds two drinks per day (Klastky et 
al. 1977; Xin et al. 2001). Recommendations for individuals who drink indicate moderate consumption, 
limiting men to ≤2 drinks per day and women to ≤1 drink per day (Appel et al. 2008). 
Clinical research trials have indicated that a diet rich in fruits and vegetables, in combination 
with low-fat dairy products and reduced saturated and total fat, can substantially lower blood pressure 
(Lawrence et al. 1997). Reduced meat intake has been shown to reduce blood pressure in normotensive 
and hypertensive individuals, independent of changes in sodium and potassium intake (Rouse et al. 
1983). In agreement with clinical trials, epidemiologic studies have shown that individuals who consume 
a vegetarian diet tend to have lower blood pressures compared to those consuming a nonvegetarian 
diet (Sacks et al. 1974; Rouse et al. 1983; Appleby et al. 2002). Observational studies have indicated 
significant inverse relationships between blood pressure and the intake of magnesium, potassium, 
calcium, and fiber (Ascherio et al. 1992; Harlan et al. 1984). However, clinical trials examining calcium 
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(Allender et al. 1996), fiber (Eliasson et al. 1992), and other nutrients, most often given as supplements, 
have found changes in blood pressure to be minimal and inconsistent (Brussaard et al. 1981; Whelton 
and Klag 1989; Whelton et al. 1992). A meta-analysis that included 16 randomized, controlled trials 
found a significant rise of 2.0 mmHg in SBP in individuals who consumed caffeine regularly (Noordzij et 
al. 2005). However, this rise in blood pressure would not be considered biologically important as it falls 
within the measurement error. This increase in SBP was much smaller in coffee drinkers compared to 
regular caffeine consumers (caffeinated beverages other than coffee) (Noordzij et al. 2005), suggesting 
that components in coffee other than caffeine may be involved. A study conducted by Jee et al. (1998) 
indicated a stronger relationship between coffee and increased blood pressure, whereas Bertrand et al. 
(1978) concluded that there was no relationship. Finally, cigarette smoking is known to acutely raise 
blood pressure, whereas epidemiological data have suggested that smokers have lower mean blood 
pressure compared to nonsmokers (Green et al. 1986), although these findings are inconsistent 
(Primatesta et al. 2001) and may be confounded by body weight. 
Inflammation 
 Inflammation is an innate and adaptive response triggered by infection and tissue injury. The 
primary objective of inflammation is to localize, remove, and repair infected or injured tissue. An acute 
inflammatory response is the initial phase of the inflammatory process, characterized by vasodilation 
and increased movement of plasma and leukocytes from blood into injured tissue. Tissue-resident 
macrophages and mast cells recognize the infection and stimulate the production of inflammatory 
mediators, such as chemokines and cytokines (Medzhitov 2008). These mediators elicit an influx of 
plasma proteins and leukocytes, primarily neutrophils, to aid in the removal of toxic agents and repair 
tissue. Neutrophils adhere to the blood vessel wall and extravasate tissue at the site of injury. Once in 
contact with the afflicted tissue, neutrophils release ROS and hydrolytic enzymes from cytoplasmic 
granules in an attempt to kill the invader (Nathan 2006). The host tissue is not protected from these 
potent effectors; host tissue damage occurs simultaneous with repair (Nathan 2002). 
 If the acute response is unsuccessful in eliminating the toxic agent, chronic inflammation 
ensues. Leukocytes, lymphocytes, and macrophages replace neutrophils in infiltrating tissue (Medzhitov 
2008). In addition to their phagocytic function, macrophages also produce cytokines, prostaglandins, 
and connective tissue elements. Both macrophages and lymphocytes increase expression of cytokines, 
which enhance the replication of epithelial cells, fibroblasts, and synthesis of extracellular matrix 
proteins (Clancy 1998). If continued attempts to engulf and destroy pathogens fail, granulomas form to 
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wall off foreign bodies (Majno 2004). Granulomas are spherical nodules comprised of organized 
macrophages that may contain additional immune and matrix cells (Adams 1976). Without regulation or 
inhibition, these processes can be detrimental to local tissue; connective tissue may accumulate, 
permanently altering tissue architecture. 
 Cytokines are immunomodulatory agents vital for signaling and cell communication. By binding 
to their specific surface receptors, cytokines mediate and alter functional states of cells and tissues 
(Medzhitov 2008). This change allows cells and tissues to adapt to the inflammatory condition. 
Cytokines mediate several responses during inflammation, including activation of the endothelium and 
leukocytes, and prompt the acute-phase response (Medzhitov 2008). Proinflammatory cytokines, 
specifically tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1), activate endothelial cells, leading to 
the production of cell adhesion molecules (CAM) (Schleimer and Rutledge 1986). CAM carry out the site-
specific inflammatory response, known as the leukocyte adhesion cascade (Figure 2). 
Leukocyte Adhesion Cascade 
The leukocyte adhesion cascade is a crucial component of the inflammatory response that takes 
place at the site of injury or inflammation. This complex process secures leukocytes on the endothelium 
leading to their transendothelial migration. The leukocyte adhesion cascade includes capture, rolling, 
slow rolling, activation, arrest, adhesion strengthening and spreading, intravascular crawling, and 
paracellular and transcellular transmigration (Figure 2) (Ley et al. 2007). During inflammation, 
proinflammatory cytokines IL-1 and TNF-α activate endothelial cells that increase expression of several 
CAM (Schleimer and Rutledge 1986). CAM are glycoproteins expressed on the surface of leukocytes and 
various tissue cell types; by binding to their respective ligands, or integrins, on the surface of target cells, 
they aid in cell-to-cell communication and cell-matrix adhesion (Elangbam et al. 1997). The four primary 
groups of CAM include the immunoglobulin superfamily, integrin receptor family, selectins, and 
cadherins (Elangbam et al. 1997). 
The selectins family and integrins, very late antigen-4 and P-selectin glycoprotein ligand-1, are 
involved in the capture and rolling of leukocytes on endothelial cells (Ley et al. 2007). Capture, or 
tethering, of leukocytes to the endothelium is mediated by L-selectin. The selectin-to-ligand bond allows 
adhesion of leukocytes to the endothelium despite blood flow (Berlin et al. 1995). In fact, L-selectin and 
P-selectin require sheer stress to bond with their ligands, and bond strength increases as this force is 
applied (Yago et al. 2007). Rolling is mediated by L-selectin, E-selectin, and P-selectin (Ley et al. 2007). 
Rolling allows leukocytes to move along the inflamed endothelium at a velocity specific to the 
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selectin/ligand interaction. L-selectin mediates the fastest rolling velocity, P-selectin a slower velocity, 
and E-selectin the slowest rolling velocity (Kunkel and Ley 1996). Slow rolling velocities increase transit 
time of leukocytes on the endothelium, promoting leukocyte activation and arrest (Steeber et al. 2005). 
Chemokines or other chemoattractants initiate the arrest of leukocytes on the endothelium 
(Campbell et al. 1996). Members of the immunoglobulin superfamily, including ICAM-1 and VCAM-1, 
mediate the arrest and firm adhesion of leukocytes via binding their leukocyte integrins, specifically 
leukocyte function antigen-1 and very late antigen-4 (Ley et al. 2007). Following arrest, adhesion 
strength increases and activated leukocytes flatten and spread on the endothelium. As leukocytes 
spread, extensions of the cell membrane protrude into the endothelial cell-body or junctions. The 
leukocyte membrane protrusions express high levels of ICAM-1 (Ley et al. 2007). Ligation of ICAM-1 by 
macrophage antigen-1 triggers the process known as crawling (Schenkel et al. 2004; Phillipson et al. 
2006). Crawling allows leukocytes to locate a preferred site for transmigration into the inflamed tissue. 
In order to emigrate into the inflamed tissue, leukocytes must pass through three barriers:  
endothelial cells, endothelial basement membrane, and pericytes. Leukocyte transmigration, also known 
as diapedesis, can take place via paracellular or transcellular routes. Paracellular migration takes place 
through endothelial-cell junctions. Transmigration requires an increase of intracellular free calcium 
concentration in endothelial cells. An intracellular calcium increase activates myosin light chain kinase, 
leading to endothelial-cell contraction and an opening of interendothlial contacts, aiding in leukocyte 
passage (Huang et al. 1993). Leukocytes are guided through endothelial junctions via a sequence of 
homophilic interactions between molecules on the leukocyte and molecules on the endothelium. 
Several molecules on the endothelium function sequentially to guide the leukocyte through the 
endothelial junctions. Members of the immunoglobulin superfamily, platelet/endothelial cell adhesion 
molecule 1 and junctional adhesion molecule A, located near the luminal surface direct leukocytes to 
endothelial cell junctions. The non-immunoglobulin molecule, CD99, follows the action of 
platelet/endothelial cell adhesion molecule 1, guiding the leukocyte through the endothelial junctions to 
the basement membrane. 
Transcellular migration involves leukocyte engulfment and transport through thin areas of the 
endothelium. Ligation of ICAM-1 triggers ICAM-1 translocation and the formation of vesiculo-vacuolar 
organelles, which create an intracellular channel in the endothelium allowing leukocytes to migrate 
(Cinamon et al. 2004; Millan et al. 2006). Ezrin, radixin, and moesin proteins may act as a link between 
cytoskeletal protein and ICAM-1 (Barreiro et al. 2002), together forming ‘docking structures’ or 
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‘transmigratory cups’ to structurally support the cell during transcellular migration (Carman and 
Springer 2004). It is possible that many of the molecules associated with paracellular transmigration are 
involved in the engulfment and transport of leukocytes through the endothelium. Following migration 
through the endothelial barrier, leukocytes penetrate the endothelial basement and the pericyte sheath. 
During transendothelial migration, leukocytes are often physically altered to aid in further migration 
(Nourshargh and Marelli-Berg 2005). This migration commonly occurs at regions of low protein density 
in the matrix and gaps between pericytes (Wang et al. 2006). 
Figure 2. Leukocyte adhesion cascade. E-selectin, Leukocyte-endothelial cell adhesion molecule; VCAM-
1, Vascular cell adhesion molecule 1; ICAM-1, Intercellular cell adhesion molecule 1. (Ley et al. 2007) 
Cell Adhesion Molecules 
Endothelial-leukocyte adhesion molecule-1 
E-selectin-1 is a member of the selectins family and is expressed by cytokine-activated 
endothelial cells. E-selectin binds to the integrin platelet-leukocyte adhesion molecule (P-selectin) 
glycoprotein ligand-1, which is expressed by neutrophils, monocytes, and lymphocytes (Moore et al. 
1995). The primary function of E-selectin is to mediate the capture and slow rolling of leukocytes along 
the endothelium. In addition to leukocyte capture, E-selectin may also recruit memory T cells to sites of 
inflammation, primarily inflammation involving the skin (Kansas 1996; Picker et al. 1991). E-selectin 
expression increases within the first few hours of inflammatory reactions and peaks within 24 hours. 
However, expression may remain high during chronic inflammatory conditions, such as psoriasis (Kansas 
1996). 
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Vascular cell adhesion molecule-1 
VCAM-1 is a member of the immunoglobulin superfamily and is expressed by cytokine-activated 
endothelial cells (Sano et al. 1995), smooth muscle cells (Ardehali et al. 1995), macrophages (Van Oosten 
et al. 1995), fibroblasts (Meng et al. 1995), bone marrow stromal cells (Bevliacqua 1993), and neurons 
(Birdsall et al. 1992). VCAM-1 binds to the integrin very late antigen-4, found on all leukocytes except 
neutrophils (Elangbam et al. 1997; Elices et al. 1990). In addition to recruiting leukocytes, VCAM-1 
mediates the firm adhesion of monocytes, lymphocytes (Carlos et al. 1990), basophils, and eosinophils 
to endothelial cells (Bochner et al. 1991). 
Intercellular adhesion molecule-1 
ICAM-1 is a member of the immunoglobulin superfamily and is expressed by cytokine-activated 
endothelial cells, leukocytes, dermal fibroblasts, and melanocytes (Elangbam et al. 1997; Johnson et al. 
1989). ICAM-1 binds to the ligands leukocyte function antigen-1 (CD11a/CD18) and macrophage 
antigen-1 (CD11b/CD18), found on neutrophils, T cells, and macrophages. Similar to VCAM-1, ICAM-1 
aids in the localization and adhesion of leukocytes to areas of inflammation. However, unlike VCAM-1, 
ICAM-1 participates in neutrophil adhesion to activated endothelium. Beyond its function as an 
adhesion molecule, ICAM-1 has been characterized recently in playing a role in signal transduction. 
Cell Adhesion Molecules, Inflammation, and Atherosclerosis 
Inflammation and Atherosclerosis 
The array of risk factors contributing to the development of CVD have been described as inter-
related processes, characterized by an underlying inflammatory condition leading to atherosclerosis 
(Ross 1993). These risk factors, including obesity, diabetes, hyperlipidemia, and HTN have been 
recognized for the chronic inflammatory state they induce (Ross 1993). This inflammatory state 
persistently activates the endothelium, upregulating the expression of CAM (Schleimer and Rutledge 
1986). Recruited leukocytes and monocytes extravasate the endothelium and begin to accumulate 
lipids, initiating atheroma formation (Zimmerman et al. 1992). Lipid-laden macrophages and smooth 
muscle cells accumulate within the arterial wall, creating a raised atherosclerotic lesion, thus narrowing 
blood vessels. With continued narrowing of the blood vessels, myocardial ischemia may occur, leading 
to angina and myocardial infarction. Calcium eventually collects in atherosclerotic plaques, making them 
brittle and vulnerable to rupture. The calcified plaque can cause bleeding and thrombi formation, 
potentially occluding local arteries or detaching to cause an embolism (Demerath et al. 2001). 
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Factors Related to Cell Adhesion Molecule Expression 
 Adhesion molecules are shed from the surface of cells and exist in soluble form in circulation, 
allowing non-invasive quantification of their expression (Rothelin et al. 1991; Gearing et al. 1992). 
Measuring serum concentrations of soluble adhesion molecules may have a prognostic role in 
identifying inflammatory conditions that increase the risk of atherosclerotic CVD. The expression of 
adhesion molecules has been related to age, gender, smoking, cancer, and disease. Increased expression 
of CAM has been identified in overt CVD and inflammatory (but not preclinical) conditions, such as 
cancer, obesity, diabetes, hyperlipidemia, HTN, and endothelial dysfunction. 
 Age 
 Studies examining rodents have consistently found an increase in the expression of CAM as 
animals age (Lakatta 2003). However, human studies have found no relationship between soluble 
adhesion molecules and age, with the exception of a positive association between age and sVCAM-1 
(Blann et al. 1996; Demerath et al. 2001; DeSouza et al. 1997; Morisaki et al. 1997; Rohde et al. 1998). 
The increase in sVCAM-1 may be due to the natural increase in blood pressure that is associated with 
age, which in turn activates endothelial cells and increases sVCAM-1 expression. The question remains 
as to why only sVCAM-1 has been noted to increase with age. 
Gender 
Gender differences in CAM expression are attributed to endogenous production of estrogen and 
androgen. Estradiol, the most biologically active female hormone, is known to have powerful 
cardioprotective effects, including promotion of vasodilation, reduction in platelet aggregability, and 
maintenance of endothelial cell integrity (Nasr and Breckwoldt 1998). In addition, estrogen has been 
reported to reduce the expression of adhesion molecules in vitro (Nasr and Breckwoldt 1998). 
Androgens have been reported to increase plaque formation in testosterone treated chicks and 
monkeys. More recently, human umbilical vein endothelial cells exposed to the androgen 
dihydrotestosterone exhibited increased monocyte adhesion to the endothelium and increased 
expression of sVCAM-1 (McCrohon et al. 1999). Although sex differences are expected in CAM 
concentrations, these distinctions have not been consistently reported. Demerath et al. (2001) and 
Blann et al. (1996) found significantly higher sE-selectin concentration in healthy men compared to 
healthy women; however, sICAM-1, sVCAM-1, and sP-selectin were not significantly different. It is 
unknown why a gender difference has only been noted for sE-selectin. 
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Smoking 
Smoking increases the susceptibility of LDL to oxidation (Steinberg 1997), which in turn 
stimulates endothelial cells and surface expression of CAM (Frostegard et al. 1993). Smoking has also 
been shown in hypercholesterolemic individuals to enhance LDL oxidation synergistically, potentiating 
endothelial dysfunction (Heitzer et al. 1996). Smoking has also been shown to be positively correlated 
with sICAM-1 (Koundouros et al 1996; Blann et al 1997), sE-selectin, and sP-selectin (Demerath et al. 
2001). However, this association was only present in active smokers, since passive smokers and ex-
smokers have been shown to have similar CAM concentrations compared with non-smokers (Demerath 
et al. 2001). 
Cancer and other diseases 
Adhesion molecules have been implicated in various stages of tumor progression, metastasis, 
and disease (McCarthy et al. 1991). Banks et al. (1993) found significantly higher sVCAM-1 and sICAM-1 
concentrations in patients with various malignancies, including myeloma, Hodgkins’s disease, non-
Hodgkin’s lymphoma, ovarian, breast, gastrointestinal, renal, and bladder cancers compared to healthy 
controls. Soluble E-selectin was significantly higher in individuals with ovarian, breast, and 
gastrointestinal cancers compared to controls (Banks et al. 1993). Increased sVCAM-1 has also been 
found in individuals with chronic inflammatory conditions, such as rheumatoid arthritis and autoimmune 
diseases (Sasseville et al. 1992), whereas elevated sICAM-1 concentration has been indicated in liver 
disease. 
Obesity 
Regardless of blood pressure, obese individuals had higher circulating sICAM-1, sVCAM-1, and 
sE-selectin concentrations compared to their non-obese hypertensive and normotensive counterparts 
(Demerath et al. 2001; Ferri et al. 1999). Ferri et al. (1999) reported significant reductions in circulating 
sICAM-1, sVCAM-1, and sE-selecting following significant BMI reduction (32.9 ± 1.8 to 31.2 ± 2.1, P=0.02) 
as a result of a 12 week energy-restricted diet. A reduction in weight and/or BMI results typically in loss 
of adipose tissue. Adipose tissue expresses a variety of secretory proteins, including TNF-α and 
adiponectin (Arita et al. 1999; Hotamisligil et al. 1993). As mentioned earlier, TNF-α activates endothelial 
cells to release CAM. Ouchi et al. (1999) reported that adiponectin acted as a beneficial endogenous 
modulator of endothelial cell function via its suppression of TNF-α action on endothelial cells. 
Paradoxically, adiponectin concentrations are significantly lower in obese subjects than non-obese 
subjects, despite adiponectin secretion occurring exclusively from adipose tissue (Arita et al. 1999). 
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Thus, the lower concentration of plasma adiponectin in obese individuals allows greater TNF-α action on 
endothelial cells, promoting CAM expression and the leukocyte adhesion cascade. Adiponectin is also 
known to improve insulin sensitivity (Hotta et al. 2000). The suppressed expression of adiponectin with 
obesity increases the risk of obese individuals to become insulin resistant and/or diabetic. 
Diabetes 
Several investigators have found higher concentrations of VCAM-1, ICAM-1, and E-selectin-1 in 
insulin-dependent diabetic (Fasching et al. 1996) and non-insulin-dependent diabetic individuals (Blüher 
et al. 2002; Boulbou et al. 2005; Kado and Nagata 1999) compared to healthy individuals (Cominacini et 
al 1995; Derosa et al. 2010; Steiner et al. 1994). Blüher et al. (2002) evaluated CAM concentration during 
various glucose and insulin states and found that sICAM-1, sVCAM-1, and sE-selectin were positively 
correlated with fasting plasma glucose (r = 0.59, P < 0.001), 2-hour oral glucose tolerance test (r = 0.70, 
P< 0.01), and hemoglobin A1c (r = 0.61, P < 0.05). Unlike sICAM-1 and sVCAM-1, sE-selectin was also 
correlated with fasting insulin concentration (r = 0.62, P < 0.05). Individuals with both chronic 
hyperglycemia and hyperinsulinemia had higher plasma CAM concentrations compared to those with 
hyperinsulinemia alone. Thus, Blüher et al. (2002) concluded that increased CAM concentration in 
diabetic individuals was likely a result of chronic hyperglycemia. Individuals with insulin resistance and 
hyperglycemia (those with Type II diabetes mellitus) are at serious risk of endothelial dysfunction. The 
chronic periods of hyperglycemia related to insulin resistance lead to the production of advanced 
glycation endproducts (AGE). Advanced glycation endproducts are known to induce ROS, and thus 
promote vascular inflammation. In fact, acute hyperglycemia has been shown in humans in vivo to 
reduce nitric oxide and impair endothelium-dependent vasodilation (Williams et al. 1998). 
Hyperlipidemia 
Hyperlipidemia causes activation of the endothelium, stimulating the release of CAM and the 
leukocyte adhesion cascade. Excess LDL in the circulation promotes infiltration of LDL in the intimal layer 
of the artery, signaling an inflammatory response. In addition, LDL may undergo oxidation or enzymatic 
damage, further stimulating the production of CAM. Individuals with high triglycerides (911 ± 111 
mg/dL) compared to controls (97 ± 7 mg/dL) had significantly higher sVCAM-1 and sICAM-1 
concentrations (Hackman et al. 1996). Soluble ICAM-1 concentration was found to be significantly higher 
in individuals with high total cholesterol (345 ± 16 mg/dL)  compared to controls (201 ± 9 mg/dL). 
Individuals with atherosclerosis in addition to hyperlipidemia had a significantly higher concentration of 
sVCAM-1 (977 ± 143 vs 566 ± 37 ng/mL, P ≤ 0.0004) compared to individuals with hyperlipidemia alone 
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(Hackman et al. 1996). Soluble ICAM-1 and sVCAM-1 concentrations were also significantly higher in 
individuals who exhibited hyperlipidemia plus any other risk factor (Hackman et al. 1996). 
Hypertension 
The relationship between HTN and CAM may be a key component to the increased risk of 
atherosclerotic CVD associated with HTN. Individuals with essential HTN were reported to have higher 
serum sICAM-1 (Chae et al. 2001; DeSouza et al. 1997), sVCAM-1 (DeSouza et al. 1997), and sE-selectin 
(Blann et al. 1994) concentrations compared to normotensives (Buemi et al. 1997). Even during acute 
elevations in blood pressure, serum concentrations of sICAM-1, sVCAM-1, and E-selectin increased in 
both normotensive and hypertensive individuals (Buemi et al. 1997). A cross-sectional study of 508 
healthy men found that increases in SBP were significantly associated with increased sICAM-1 
concentration, whereas increases in both SBP and DBP were significantly associated with increased IL-6 
concentration, a proinflammatory cytokine (Chae et al. 2001). As described previously, reduced 
circulating adiponectin has been associated with greater CAM expression. Adamczak et al. (2003) 
reported significantly lower adiponectin concentration in hypertensive individuals compared to age-, 
gender-, and BMI-matched normotensive individuals. Adamczak etl al. (2003) also demonstrated a 
significant negative correlation between adiponectin and blood pressure. The increased expression of 
adhesion molecules associated with HTN may explain the relationship between HTN and endothelial 
dysfunction. 
Endothelial dysfunction 
Endothelial dysfunction refers to a condition of reduced vasodilation, which coincides with a 
proinflammatory and prothrombotic state (Endemann and Schiffrin 2004). The impairment of 
vasodilation has been indicated in metabolic syndrome and dyslipidemia (Engler et al. 2003), type 1 
diabetes (Bechman et al. 2003), type 2 diabetes (Rizzoni et al. 2001; Schofield et al. 2002), coronary 
artery disease (Monnink et al. 2002), congestive heart failure (Lendmesser et al. 2002), and chronic renal 
failure (Bolton et al. 2001; Thambryrajah et al. 2000). Endothelial dysfunction may not only be related to 
existing CVD, but also as a component of its development. 
Potential risk factors for endothelial dysfunction include obesity (Raitakeri et al. 2004), 
hyperhomocysteinemia (Virids et al. 2001), physical inactivity (Green et al. 2003), and smoking (Oida et 
al. 2003). The mechanisms related to the pathophysiology of endothelial dysfunction are complex, and 
commonly involve nitric oxide, oxidative excess, and inflammation (Endemann and Schiffrin 2004). 
Hypertensive individuals often exhibit oxidative excess, leading to diminished nitric oxide production 
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and endothelial dysfunction (Endemann and Schiffrin 2004; Taddei et al. 1998). Oxidative excess limits 
reductase function, causing the formation of excess ROS. Reactive oxygen species upregulate the 
expression of adhesion molecules VCAM-1 and ICAM-1, as well as other chemotactic molecules, 
promoting a proinflammatory state within the endothelium (Endemann and Schiffrin 2004; Griendling 
and FitzGerald 2003). 
Hypertensive individuals have an elevated concentration of Ang II, also implicated in the 
pathophysiology of endothelial dysfunction. Ang II infusion has been shown to increase ROS and to 
promote vascular inflammation, leading to endothelial dysfunction (Rajagopalan et al. 1996; Touyz and 
Schiffrin 1999). Administration of Ang II directly stimulated VCAM-1 (Pueyo et al. 1998) and ICAM-1 
(Pastore et al. 1999) expression in endothelial cells, and E-selectin expression in coronary endothelial 
cells (Grafe et al. 1997). Expression of VCAM-1 may be induced or mediated by the redox-sensitive 
transcription factor nuclear factor-κB (NF-κB) (Collins et al. 1995). Ang II activates NF-κB in endothelial 
cells (Pueyo et al. 1998), and NF-κB in turn regulates an inflammatory and proliferative cell response 
(Brand et al. 1996), which has been indentified in endothelial cells and atherosclerotic tissue (Brand et 
al. 1996). These mechanisms suggest that increases in adhesion molecule expression are not only a 
direct, but also indirect, consequence of HTN. 
Cardiovascular disease 
Adhesion molecules have been implicated in the progression and consequences of 
atherosclerotic CVD. Soluble ICAM-1 (Rohde et al. 1999) and sVCAM-1 (DeCaterina et al. 1997; Rohde et 
al. 1998) have been identified as markers of the severity of carotid atherosclerosis, and in addition to sE-
selectin, have been detected in human atherosclerotic lesions (Davies et al. 1993). Unlike sVCAM-1, 
sICAM-1 has been found to be an independent risk factor for myocardial infarction (Hwang et al 1997; 
Ridker et al. 1998) and has consistently been associated with established CVD risk factors in males 
(Demerath et al. 2001; Rohde et al. 1999). Blann and McCollum (1994) also found significantly higher 
concentration of sICAM-1, but not sVCAM-1, in patients with ischemic heart disease and peripheral 
vascular disease compared to that of age-matched control subjects. Elevated sE-selectin expression has 
been reported following ischemic stroke (Frinhs et al. 1997) and disseminated intravascular coagulation. 
The elevated expression of CAM in chronic inflammatory conditions, as well as overt CVD, suggests that 
adhesion molecules may serve as markers of atherosclerosis and the consequent development of CVD 
(Hwang et al. 1997). The reduced expression of CAM may indicate suppressed inflammatory activity, 
with a subsequent decreased risk of atherosclerotic CVD. Identifying clinical interventions that may 
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reduce CAM concentrations in high risk individuals, such as hypertensives, may also provide an avenue 
to secondary prevention of atherosclerosis. 
Milk Beverage Intervention 
 Hypertensive individuals are at an increased risk of inflammation and atherosclerotic CVD. 
Furthermore, CAM concentrations are typically elevated in persons with HTN, inflammation, and CVD. A 
reduction in blood pressure or CAM concentrations may reduce the risk of atherosclerotic CVD via 
modulation of the inflammatory state. Previous investigations have indicated an inverse relationship 
between milk, either cow or soy, and blood pressure. Identifying a dietary intervention to reduce CAM 
concentrations in at-risk individuals may provide a secondary preventive measure for atherosclerotic 
CVD. 
Cow’s Milk 
Blood pressure response 
The relationship between blood pressure and dairy intake was reported in the first National 
Health and Nutrition Examination Survey (NHANES I) analysis, in which a cross-sectional study of greater 
than 10,000 individuals revealed that low milk consumption was related to increased prevalence of HTN 
(McCarron et al. 1984). A study of Puerto Rican men reported that those who did not drink milk had a 
two-fold greater prevalence of HTN compared to men who drank at least 1 L milk/day (Farcia-Palmieri et 
al. 1984). The relationship between HTN and reduced milk intake has also been reported in American 
(Ackley et al. 1983) and Italian (Trevisan et al. 1988) population studies. One large observational study of 
university graduates indicated that low-fat dairy consumption, but not whole-fat dairy consumption, 
was associated with a lower risk of incident HTN (Alonso et al. 2005). 
Following these and other epidemiological reports, intervention studies investigated the impact 
of dairy consumption on blood pressure. The well recognized DASH trial examined a diet rich in fruits, 
vegetables, and low-fat dairy products consumed by normotensive and hypertensive subjects. Mean 
blood pressure was significantly reduced in both normotensive and hypertensive subjects (mean SBP by 
5.5 mmHg and DBP by 3.0 mmHg); however, blood pressure reduction (mean SBP by 11.4 mmHg and 
DBP by 5.5 mmHg) in the hypertensive subjects was greater than in the normotensive subjects (Appel et 
al. 1997; McCarron and Reusser 1999). Milk supplementation has been shown to reduce blood pressure 
in several studies. Buonopane et al (1992) reported a significant reduction in SBP and DBP in adults who 
were supplemented with one quart of skim milk per day for eight weeks. Hilary et al. (2000) examined 
the effect of a fourweek supplementation of skim, high calcium skim, or potassium-enriched high 
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calcium skim milk on blood pressure in healthy subjects greater than 40 years of age. Seated SBP was 
significantly reduced in all treatment groups; however, there was no change in DBP. The greatest 
reduction in SBP was in the potassium-enriched high calcium skim milk group (Hilary et al. 2000). In 
another study, a significant reduction in SBP (6.8 mmHg, P < 0.01) and DBP (4.3 mmHg, P < 0.01) was 
observed for obese African American individuals supplemented with a high dairy calcium diet (3 servings 
per day) compared to a low dairy calcium diet (<1 serving per day) (Zemel et al. 2005). Although 
evidence strongly suggests a relationship between dairy intake and reduced blood pressure, this has not 
been demonstrated in all studies. Healthy older adults (55-85 years of age) who were advised to 
increase skim or 1% milk consumption by 3 cups per day did not exhibit a greater reduction in blood 
pressure compared to matched controls who did not change their diet (Barr et al. 2000). One study 
found that supplementation with whole-fat milk actually increased significantly SBP, but not DBP, in 
young normotensive adults (18-24 years of age) (Alonso et al. 2009). 
Initially, it was assumed that dairy calcium was responsible for the inverse relationship between 
dairy consumption and blood pressure. Research has shown that individuals with HTN have reduced 
serum ionized calcium (McCarron 1982) and non-dairy calcium supplements also have been effective in 
reducing blood pressure (Belizan et al. 1983; Dwyer et al. 1998). Yet, additional investigations have 
found that the proteins in milk, casein and whey, either as whole proteins or their degradation products, 
also contribute to the blood pressure-reducing effect of dairy products. Pal and Ellis (2010) recently 
investigated changes in blood pressure in overweight or obese subjects supplemented with whey 
protein isolate, sodium caseinate, or a glucose control, which they consumed with 250 mL of water, two 
times daily for 12 weeks. In the whey and casein groups, SBP was significantly reduced at 6 and 12 
weeks compared to baseline SBP, while DBP was significantly reduced at 12 weeks compared to 
baseline. Although in the treatment groups blood pressure was significantly reduced compared to 
baseline values, only the reduction of DBP was significantly different among the treatment and control 
groups. 
Attention has recently turned toward milk-derived bioactive peptides, the degradation products 
of proteins. These peptides are released during food processing or digestion and have been credited 
with a number of physiological functions including antihypertensive, immunomodulatory, and 
antioxidative properties (Jäkälä and Vapaatalo 2010). The greatest interest has focused on particular 
tripeptides released during fermentation of milk with specific lactobacilli strains (Jäkälä and Vapaatalo 
2010). The primary milk-derived bioactive peptides are casein-derived Ile-Pro-Pro and Val-Pro-Pro 
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(Jäkälä and Vapaatalo 2010). These tripeptides have been shown to inhibit angiotensin-converting 
enzyme in vitro (Nakamura et al. 1995) and have been effective in reducing blood pressure in humans 
(de Leeuw et al. 2009; Nakamura et al. 2009; Yoshizawa et al. 2009). Two recent meta-analyses 
examined blood pressure response to peptides and found similar results. Xu et al. (2008) found 
significant decreases of 4.8 mmHg in SBP and 2.2 mm in DBP; likewise, Pripp (2008) found significant 
decreases of 4.6 mmHg in SBP and 2.2 mmHg in DBP. Nearly all clinical trials in this area have studied 
the long-term effects of lactotripeptides on blood pressure. However, van der Zander et al. (2008) 
observed an acute and significant reduction of 2 mmHg in SBP following ingestion of a lactotripeptide-
containing milk product. After several long-term studies examining these effects, researchers have 
found that supplementing pure tripeptides does not produce as strong an antihypertensive effect as the 
milk products themselves (Jauhianinen et al. 2005; Sipola et al. 2001). It is important to note that 
although changes in blood pressure have been found to be statistically significant, the actual value is 
relatively small and cannot be evaluated independent from measurement error, casting particular doubt 
on the biological relevance for DBP reduction. 
Cow’s milk may modulate blood pressure through several of its components:  the proteins, 
minerals (high in calcium, phosphorus, potassium, selenium), or the combination of both in a milk 
product. Cow’s milk consumption may be a relatively simple potential clinical intervention to reduce 
blood pressure, thereby reducing inflammation and the risk of atherosclerotic CVD. Provided cow’s milk 
consumption results in a simultaneous reduction in blood pressure and in CAM concentration, the risk of 
atherosclerotic CVD might be further reduced with this dietary intervention. 
Cell adhesion molecule expression 
Little research has been conducted on the effect of dairy consumption on inflammatory 
markers, such as CAM. In theory, the relationship between high blood pressure and increased CAM 
expression would suggest that a reduction in blood pressure following dairy consumption would, in turn, 
reduce CAM. Wennersberg et al. (2009) investigated the effects of an increased intake of dairy products 
on several factors in overweight individuals who typically consume a low amount of dairy foods. 
Individuals who consumed 3-5 servings of dairy products daily did not exhibit any significant changes in 
sVCAM-1 concentration compared to the control group, although when sexes were examined 
separately, sVCAM-1 was significantly (P = 0.001) reduced in women who increased their intake. A 
crossover study of 486 adult Iranian women (40-60 years of age) collected dairy intake data based on a 
food frequency questionnaire and examined markers of inflammation, including sVCAM-1 
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concentration. Low-fat dairy intake was inversely correlated to sVCAM-1; however, high-fat dairy intake 
was positively correlated to sVCAM-1 (Esmaillzadeh and Azadbakht 2010), illustrating that the fat 
content of milk may be a critically important determinant of the inflammatory response. These 
controversial results, along with the limited number of studies in this area of research, indicate that 
further investigation to verify a relationship between cow’s milk and CAM concentrations is needed. 
Soy Products 
Blood pressure response 
Soy foods have been suggested to improve CVD-related risk factors, and considerable interest 
has been given to their potential hypocholesterolemic properties (Sacks et al. 2006; Zhan and Ho 2005). 
Two characteristic components of soy products are the high-quality soy protein and bioactive molecules 
associated with the protein, particularly the isoflavones. Isoflavones have been reported to exert several 
physiological responses in animals, including arterial vasodilation (Anthony et al. 1998), serum 
cholesterol reduction (Anthony et al. 1998), and atherosclerosis inhibition (Clarkson et al. 2001). 
Investigators have often used soy protein supplements without considering the isoflavone content or 
the preparation of the soy protein, which may partially explain the wide variability in results. The 
isoflavone content of the product depends heavily upon the processing. If the protein is extracted with 
an alcohol wash, as might be the case with soy protein isolate, a substantial amount of isoflavones will 
be lost (Sacks et al. 2008). The three primary isoflavones (in aglycone form) found in soybeans are 
genistein, daidzein, and glycitein; the quantity of each in soy products differs greatly due to the variety 
of processing techniques (Sacks et al. 2008). Since the late 1990s, most published studies state the 
isoflavone content (form and dose) provided to participants, since investigators consider these 
particulars as important variables that can markedly affect the outcome. 
A number of studies have been conducted to examine the influence of soy protein consumption 
on CVD-related risk factors, including blood pressure. However, the subjects are often postmenopausal 
women, the amount of soy protein and isoflavones vary greatly, and the results are quite inconsistent. A 
cross-sectional study in Japanese men and peri- or postmenopausal women evaluated the relationship 
between estimated soy product intake and blood pressure. Soy product intake was negatively correlated 
in men to DBP (r = -0.12, P = 0.04) and to SBP (r = -0.10, P = 0.09), whereas no significant correlations 
were found in women (Nagata et al. 2003). He et al. (2005) supplemented normotensive and 
hypertensive men and women in the People’s Republic of China with isolated soybean protein (40 
g/day) incorporated into cookies for 12 weeks. The soy protein contained 76.4 mg of total isoflavone 
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(44.9 mg genistein, 26.5 mg daidzein, 4.9 mg glycitein [aglycone units]). Among the supplemented 
group, SBP and DBP were reduced by 7.9 mmHg and 5.3 mmHg, respectively, for the hypertensive 
individuals, whereas were reduced by 2.3 mmHg and 1.3 mmHg, respectively, for the nonhypertensive 
individuals (He et al. 2005). Using a crossover design, Jenkins et al. (2002) provided hyperlipidemic men 
and postmenopausal women with a low fat control, a high isoflavone (50 g soy protein and 73 mg 
isoflavones), and a low isoflavone (52 g soy protein and 10 mg isoflavones) diet, each daily for one 
month period. Blood pressure reduction only occurred in men on the high isoflavone diet compared to 
control, whereas no significant difference was noted between the high- and low-isoflavone diets. Men 
and postmenopausal women supplemented with 28 g soy protein isolate powder (19.9 g protein, 42.0 
mg isoflavone [26.8 mg genistein, 13.1 mg daidzein, 1.8 mg glycitein]) twice daily for 3 months 
experienced a significant decrease in mean blood pressure, SBP, and DBP compared to the control group 
(Teede et al. 2001). In the supplemented group, mean reductions in SBP and DBP were 7.5 and 4.3 
mmHg, respectively, compared to the 3.6 and 1.9 mmHg, respectively, in the casein control group. The 
most dramatic results were reported by Rivas et al. (2002), in which men and women with mild to 
moderate HTN were supplemented with 500 mL of a high isoflavone soy milk (80 mg genistein and 63 
mg daidzein per 500 mL) twice per day for three months. After supplementation, SBP and DBP, 
respectively, were significantly reduced in the soy milk group (18.4 ± 10.7 mmHg, P < 0.0001 and 15.9 ± 
9.8 mmHg, P < 0.0001) compared to the cow’s skim milk group (1.4 ± 7.2 mmHg and 3.7 ± 5.0 mmHg). 
Although the evidence presented herein suggests a relationship between soy product intake and 
reduced blood pressure, several studies investigating soy protein or soy isoflavones and blood pressure 
have reported no effect (Hermansen et al. 2001; Hodgson et al. 1999; Nestel et al. 1997; Simons et al. 
2000). Teede et al. (2006) supplemented hypertensive men and postmenopausal women with soy cereal 
(40 g protein, 118 mg total isoflavones) for 6 months and examined the 24 hour blood pressure 
response. Mean blood pressure during 24 hours did not change within or between soy and placebo 
groups. However, five years prior, Teede et al. (2001) supplemented healthy men and postmenopausal 
women for 3 months with the same soy cereal and examined single blood pressure measurements. 
Reductions in mean SBP and DBP, respectively, were significantly greater in the soy milk (7.5 mmHg and 
4.3 mmHg) compared to the placebo (3.5 mmHg and 1.9 mmHg) group. 
Despite apparently conflicting results, after compiling 14 randomized controlled studies, the 
most recent meta-analysis examining soy isoflavone extract supplements and blood pressure in 
normotensive or prehypertensive adults found a significant overall reduction in SBP of 1.9 mmHg, but 
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not DBP, in the soy isoflavone compared to placebo controlled treatment. Daily isoflavone supplements 
varied between 25 and 375 mg total isoflavones and duration ranged from 2 to 24 weeks. Treatment 
had the greatest effect in studies lasting longer than 3 months (Taku et al. 2010). However, this small 
change in SBP calculated from previously published studies would be near impossible to detect given 
measurement error, thus casting doubt on its biological relevance. Soy protein may reduce blood 
pressure through a variety of its components:  the proteins, its isoflavones, other bioactive components, 
or the combination of bioactive components and protein in soy products. The question becomes 
whether or not the soy protein effect is sufficiently robust to produce a meaningful reduction in blood 
pressure in most individuals. If it is, soy product intake may be a relatively simple dietary intervention to 
reduce blood pressure, thereby reducing inflammation, CAM concentration, and the risk of 
atherosclerotic CVD. 
Cell adhesion molecule expression 
 A decrease in blood pressure and/or serum cholesterol reduces overall CVD risk. A direct 
measure of inflammatory status at the molecular level may be CAM expression. Research has shown 
that soy product consumption may be associated with a reduction in blood pressure and serum 
cholesterol. A concurrent or independent reduction in adhesion molecule expression following soy 
intake would further support the relationship between soy consumption and decreased CVD risk. 
The isoflavones found in soy foods, genistein, daidzein, and glycitein (and their respective 
glycosides), have been reported to have anti-inflammatory properties (Chacko et al. 2005; Wei et al. 
1995). Atteritano et al. (2007) supplemented postmenopausal women with 54 mg/day of genistein for 2 
years and found sVCAM-1 and sICAM-1 to be significantly (P < 0.05) reduced compared to placebo. 
Colacurci et al. (2005) supplemented postmenopausal women with an isoflavone tablet and also 
reported a significant reduction in CAM, including sVCAM-1, sICAM-1, and E-selectin. Postmenopausal 
women with metabolic syndrome consumed a DASH diet in addition to replacing one serving of red 
meat with 30 g of soy protein (281 mg total isoflavones) or 30 g soy nuts (340 mg total isoflavones). The 
female subjects exhibited a significant reduction in sE-selectin concentration in response to both diets 
compared to the DASH diet alone (Azadbakht et al. 2007). 
Although some studies agree there is a relationship between soy product intake and reduced 
CAM concentrations, others have not reported these same results. Steinberg et al. (2003) investigated 
the effects of 25 g soy protein isolate 3 times per day with high isoflavones (107 mg total isoflavones), 
25 g ethanol-washed soy protein isolate with low isoflavones (2 mg total isoflavones), and 25 g milk 
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protein (no isoflavones) for 6 weeks on endothelial function in healthy postmenopausal women. No 
change was observed among the three treatment groups. Nikander et al. (2003) also supplemented 
postmenopausal women with soy isoflavones (114 mg/day), reporting no significant difference in CAM 
between treatment and placebo groups. However, serum daidzein (r= 0.39; P < 0.003) and genistein (r= 
0.38; P < 0.004) concentrations were inversely associated with E-selectin concentration (Nikander et al. 
2003). 
A potential explanation for the cardioprotective effect of soy isoflavones is that they exert 
activity similar to that of estrogen and have particular affinity for estrogen receptor β. Estrogen 
enhances nitric oxide production, modulating vasodilatory responses and improving endothelial function 
(Hall et al. 2005). Although isoflavones do not exert the same potency as estrogen, isoflavone intake can 
elevate circulating isoflavone concentrations up to 10,000 fold greater than that of endogenous 
estrogen (Aldercreutz et al. 1993). In addition, genistein has been shown to have a potent anti-
inflammatory action by inhibiting monocyte adhesion to cytokine-activated endothelial cells (Chako et 
al. 2005). 
In addition, the variable results in response to soy products may be due to the ability of 
individuals to produce equol, an endogenous degradation product of daidzein, which has been 
implicated as a highly bioactive metabolite. However, intestinal bacteria that degrade daidzein to equol 
are evidently not universally present in all individuals (Bingham et al. 2003); most studies have indicated 
that ~30% of individuals produce equol. Studies also vary greatly in the amount of isoflavones and soy 
protein provided to subjects, in addition to different lengths of supplementation time. Perhaps the 
greatest difference among studies is with respect to subject characteristics. For example, a majority of 
published research using soy protein and isoflavones has been almost exclusively conducted in 
postmenopausal women. These results also have been inconsistent, perhaps because of differences in 
ethnicity, age, time since menopause, baseline blood pressure, or unknown host factors. Nevertheless, 
the effect of soy protein and isoflavones on CAM in men and premenopausal women at-risk for 
atherosclerotic CVD remains relatively unexplored. 
Summary 
Inflammation is related to both HTN and CAM, suggesting that the inflammatory process is 
central to an increased risk of atherosclerotic CVD. Cow’s milk and soy product consumption perhaps 
have the potential to decrease inflammation and hence attenuate the risk of atherosclerotic CVD, as 
evidenced by a reduction in blood pressure and circulating CAM concentrations in selected subjects 
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from some but not all studies. Further research is warranted to determine the extent to which cow’s 
milk or two preparations of soy milk (with different levels of isoflavones) may favorably affect blood 
pressure and/or adhesion molecules in men and premenopausal women at risk of atherosclerotic CVD 
because of their prehypertensive/Stage 1 hypertensive state. 
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ABSTRACT 
Background and Aims:  Prehypertensive and hypertensive individuals are at an increased risk of 
atherosclerotic cardiovascular disease. The role of hypertension in endothelial dysfunction and 
increased cell adhesion molecule (CAM) expression may lead to atherosclerotic progression. Soy protein 
and isoflavones have been shown to favorably alter cardiovascular disease risk factors. The aim of this 
study was to determine the effect of daily cow’s milk compared with soy beverage prepared from whole 
soy bean (WSB) or soy protein isolate (SPI) on soluble cell adhesion molecules. 
Methods:  We enrolled healthy prehypertensive/Stage 1 hypertensive men (n=60, aged 18–63 yr) and 
premenopausal women (n=8, aged 20–48 yr) and randomized them to one of three beverage groups for 
8 weeks of treatment:  cow’s milk (600 mL/d), soy beverage (840 mL/d) prepared from SPI (30.1 mg total 
isoflavones/d [aglycone form]) or prepared from WSB (91.4 mg total isoflavones/d [aglycone form]). We 
measured soluble vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 
(ICAM-1), and endothelial-leukocyte adhesion molecule-1 (E-selectin) concentrations at baseline and 
week 8. 
Results:  Treatment did not alter soluble CAM concentrations. Time had an effect on VCAM-1 (-9%, P = 
0.01) and E-selectin (+4%, P = 0.01) but not ICAM-1 (+5%, P=0.86). When included as a covariate, gender 
had a significant effect on ICAM-1 (P=0.0037), whereas gender did not reach significance for E-selectin 
(P=0.067) or VCAM-1 (P=0.16). However, men had higher circulating concentrations of ICAM-1 and E-
selectin, respectively, at both baseline (P = 0.0071, P = 0.049) and week 8 (P = 0.0054, P = 0.038) than 
women. ICAM concentrations were not significantly different between prehypertensive and 
hypertensive participants. 
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Conclusion:  Prehypertensive/Stage I hypertensive individuals who consumed either cow’s milk or soy 
beverages (prepared from WSB or SPI) for 8 weeks daily did not show any change in soluble CAM 
concentrations. Consequently, we cannot suggest that daily intake of either cow’s milk or soy protein 
beverages improves circulating CAM concentrations and hence risk of atherosclerotic CVD in these 
individuals. 
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Hypertension, Isoflavones, Soy protein 
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INTRODUCTION 
Atherosclerotic cardiovascular disease (CVD) is the number one cause of death in the United 
States, accounting for more than 50 percent of all mortality (Lloyd-Jones et al. 2010). Ross (1999) 
described CVD as a condition of underlying inflammation, leading to the progression of atherosclerosis. 
Conditions implicated in perpetuating chronic inflammation include diabetes, obesity, hyperlipidemia, 
and hypertension (HTN) (Ross 1999). HTN is a primary, yet modifiable, risk factor for atherosclerotic 
CVD. In the US, 29 percent of the adult population has HTN, in addition to 37 percent who have 
prehypertension (Ostchega et al. 2008). An increase in angiotensin II concentration (Ross 1999), as well 
as a reduction in both nitric oxide (Endemann and Schiffrin 2004; Taddei et al. 1998) and adiponectin 
production (Adamczak et al. 2003), are related to HTN. HTN also increases shear stress on the vessel 
wall; endothelial cells in turn modify their morphology, gene expression, and function in response to 
shear stress (Ando & Yamamoto 2009). The chemical alterations and mechanical damage associated 
with HTN persistently activate endothelial cells, contributing to endothelial dysfunction. An excess of 
prothrombotic and proinflammatory signals coincide with endothelial dysfunction, promoting the 
expression of chemotactic molecules and cytokines, particularly tumor necrosis factor-α (TNF-α) and 
interleukin-1 (IL-1) (Endemann and Schiffrin 2004; Griendling and FitzGerald 2003). In response to these 
cytokines, activated endothelial cells express cell adhesion molecules (CAM), specifically vascular cell 
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adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and endothelial-leukocyte 
adhesion molecule-1 (E-selectin) (Schleimer and Rutledge 1986). 
These CAM are glycoproteins located on the surface of a variety of cells, mainly endothelial cells, 
and aid in cell-cell communication and cell-matrix adhesion (Elangbam et al. 1997). By binding to their 
respective integrins, or ligands, CAM perform the site-specific inflammatory response known as the 
leukocyte adhesion cascade (Ley et al. 2007). This process controls the locomotion and migration of 
leukocytes through the endothelium where they repair injured tissue or remove toxic agents. During 
chronic inflammatory states, such as HTN, this process may continue unregulated. Leukocytes, foam 
cells, and smooth muscle cells accumulate and proliferate in the subendothelial space forming a lesion 
(Ross 1999). The enlarging lesion may completely occlude the blood vessel, or collect calcium forming a 
plaque. An atherosclerotic plaque weakens the vessel wall, making it vulnerable to rupture. Ultimately 
this process may lead to myocardial infarction or stroke (Demerath et al. 2001; Ross 1999). 
Due to several mechanisms by which HTN contributes to endothelial dysfunction, hypertensive 
individuals likely express higher CAM concentrations, thus placing them at greater risk of atherosclerotic 
CVD. Soy isoflavones, bioactive molecules structurally similar to 17β-estradiol, have been hypothesized 
to protect against atherosclerotic CVD (Sacks et al. 2006; Zhan and Ho 2005). Moreover, clinical studies 
have reported that soy isoflavones increase nitric oxide production, thereby increasing arterial 
vasodilation (Anthony et al. 1998) and independently reducing CAM concentrations (Endemann and 
Schiffrin 2004; Griendling and FitzGerald 2003). A reduction in CAM expression may suppress the 
leukocyte adhesion cascade, thereby reducing accumulating leukocytes and potentially atherosclerotic 
progression. Prior investigations have indicated that hypertensive individuals have significantly greater 
concentrations of CAM compared to normotensive individuals (Blann et al. 1994; Buemi et al. 1997; 
Chae et al. 2001; DeSouza et al. 1997). However, much of the research examining the effects of soy food 
intake on these markers investigated hypercholesterolemic postmenopausal women. Therefore, the aim 
of this study was to determine the effect of soy beverage consumption versus cow’s milk on CAM 
concentrations in otherwise apparently healthy prehypertensive/Stage 1 hypertensive men and women. 
We hypothesized that soy beverages (either prepared from WSB or SPI) would reduce CAM 
concentrations in prehypertensive/Stage 1 hypertensive individuals to a greater extent than cow’s milk, 
regardless of whether or not blood pressure was impacted. Further, we anticipated that the soy 
beverage prepared from WSB, due to its higher isoflavone content, would reduce CAM concentrations 
to a greater extent than the soy beverage prepared from SPI. 
 45   
 
 
METHODS 
Research Design 
 This study was designed to determine whether drinking soy beverage versus cow’s milk, daily for 
eight weeks would reduce circulating concentrations of sICAM-1, sVCAM-1, and sE-selectin. Blood and 
24-hour urine samples were collected at baseline and at week 8. Resting blood pressure was measured 
at baseline, 2, 4, 6, and 8 weeks. Ambulatory blood pressure was measured at baseline, 4, and 8 weeks. 
The study protocol, consent form, and subject-related materials were approved by the Institutional 
Review Boards (IRB) at Iowa State University (ID 02-199). We obtained informed consent from all 
individuals at the initial screening and after screening criteria were met. 
Subject Screening, Selection, and Characteristics 
 We recruited subjects throughout the Ames, IA region primarily through mass email listings, 
local newspaper advertisements, and the distribution of informative flyers. Those who responded were 
screened using a questionnaire to identify healthy individuals who were premenopausal women 18-50 
years of age or men 18-65 years of age, not on any medication for HTN, and had not taken antibiotics 
within the last month. Participants who gained or lost more than 10 lbs in the past six months or had a 
body mass index (BMI, kg/m2) above 35 were excluded. Vegans, vegetarians, and those on specials diets 
to lose weight or control sodium intake were excluded. We also excluded individuals with allergies or 
intolerances to milk or soy protein and those who were habitual soy product consumers. Additionally, 
we excluded pregnant or nursing mothers, peri- and postmenopausal women, or women who had a 
complete hysterectomy. A pregnancy test was completed during the screening of each female 
participant. 
 During the initial screening visit we measured 10-minute resting blood pressure (IntelliSense 
Professional HEM-907XL Digital Blood Pressure Monitor; Omron Healthcare Inc., Bannockburn, IL), 
height, weight, and waist circumference. Individuals with a SBP greater than 120 and/or DBP greater 80 
were included in the study. If SBP was greater than 160 and/or DBP was greater than 100, we required 
written permission from the participant’s physician. A randomized, single-blind taste test of the three 
milk beverages was conducted at the end of the initial screening appointment. To ensure minimal 
acceptance of treatment beverage and an ability to randomize to at least two treatments, individuals 
were excluded if he or she rated two or more of the three treatment beverages below 4 on a 1-7 scale 
(1: terrible, 4: acceptable, 7: delicious), or ≥ 2 of the 3 beverages were marked that the individual would 
not agree to consume 3.5 cups every day for 2 months. 
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Participants who met the initial screening criteria were invited to the second screening during 
which a licensed phlebotomist collected fasted blood samples for a metabolic profile. Blood glucose, 
total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, blood urea nitrogen (BUN), creatinine, 
and liver enzymes were required to fall within the reference ranges provided by the certified clinical 
laboratory (LabCorp; Kansas City, MO). If this was not the case, we required written permission from the 
participant’s physician. 
Subject Randomization and Treatment 
Qualified participants were randomly assigned to one of three groups:  cow’s milk (n=21); soy 
beverage prepared from WSB (n=23); soy beverage prepared from SPI (n=24). The composition of the 
three treatment beverages is presented in Table 1. The beverages were matched closely for energy, 
carbohydrate, protein, fat, and sodium content. Soy beverage isoflavones were extracted and analyzed 
by HPLC (Beckman Coulter; Fullerton, CA) at Iowa State University (Murphy et al. 1981). The WSB 
beverage contained a greater amount of all isoflavones compared to the SPI beverage (Table 1). Subjects 
in the cow’s milk group consumed 2.5 cups/day while limiting other dairy product intake to ≤1 
serving/day to ensure comparability with the soy beverage groups. Subjects in either of the soy 
beverage groups consumed 3.5 cups/day while asked to consume no other soy products and limit dairy 
product intake to ≤1 serving/day. Participants were asked to otherwise maintain their normal diet (with 
the exception of dairy product and soy product intake) and physical activity for the duration of the 
study. As one check on compliance, they were also asked to return each week all unused treatment 
beverages in their original containers. 
Data Collection 
Urinary Measurements 
At baseline and week 8, each subject was provided explicit directions for collecting 24-hour 
urine samples, which were measured and recorded for total volume. Aliquots were stored at -20°C. 
Concentrations of urinary sodium and potassium were analyzed by a certified clinical laboratory 
(LabCorp; Kansas City, Kansas). Extracted urinary isoflavones were analyzed by HPLC (Beckman Coulter; 
Fullerton, CA) at Iowa State University (Lundh et al. 1988; Murphy et al. 1997; Zhang et al. 1999). In 
addition to returning unused beverage containers each week, urinary isoflavone excretion was used to 
corroborate treatment adherence (Table 2). 
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Body Size and Composition Assessment 
 A trained research assistant assessed anthropometric measures for each subject. During the 
initial screening visit, height, weight, BMI, and waist circumference measurements were taken. Height 
was measured (to the nearest 0.1 cm) without shoes with a wall-mounted stadiometer (Ayrton 
stadiometer, Model S100; Ayrton Corp., Prior Lake, MN). Body weight was measured (to the nearest 0.1 
kg), with each subject wearing light clothing without shoes, using an electronic scale (Detecto Digital 
Weight Indicator, Model 768C; Cardinal Scale Manufacturing Co., Webb City, MO). Weight and height 
measures were used to calculate BMI (Table 3). Waist circumference at the natural waist line for each 
woman and one inch above the naval for men was measured with a tape measure (non-stretchable) 
while subjects stood relaxed with hands at their sides. 
Questionnaires and Dietary Intake Assessment 
 At the initial screening visit each participant completed a screening questionnaire and a soy food 
questionnaire (Kirk et al. 1999). We excluded potential participants who indicated that they consumed 
whole soybean foods or foods containing soy protein more than once per month. Following the 
screening visits, potential participants also completed a medical history questionnaire. 
 Dietary intake was assessed at baseline with the use of a three-day food diary. Participants were 
asked to record everything consumed during two consecutive weekdays followed by a weekend day. To 
calculate diet composition, this information was verified and entered into the Nutritionist Pro database 
using their software (Nutritionist Pro; AXXYA Systems, Stafford, TX) by a trained nutrition student. 
Dietary intake data are presented in Table 4. 
Serum Measurements 
A licensed phlebotomist collected fasted (10 hr) blood samples between 0600 and 0800 hr. 
Blood samples were allowed to clot for a minimum of 30 minutes. Serum was separated from whole 
blood by centrifuging for 10 minutes at 4°C @ 2000 × g and in-house aliquots were stored at -80°C until 
analyses. Serum sVCAM-1, sICAM-1, and sE-selectin were measured (Table 5) using human enzyme-
linked immunosorbent assay kits (Quantikine Immunoassay; R&D Systems; Inc.; Minneapolis, MN) with 
the use of a microplate reader (Synergy 2 Mulit-mode Microplate Reader; Biotek Instruments Inc.; 
Winooski, VT). Serum samples were diluted 20-fold for the measurement of sICAM-1 and sVCAM-1 and 
10-fold for E-selectin. Inter- and intra-assay coefficients of variation, respectively, were 3.7 and 5.2% for 
VCAM-1, 3.5 and 3.8% for ICAM-1, and 2.3 and 4.6% for E-selectin assays. Serum samples were also 
analyzed by a certified clinical laboratory (LabCorp; Kansas City, KS) for a complete metabolic profile to 
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ensure that participants were otherwise healthy (Table 3). To quantify and predict overall general CVD 
risk, parameters includuing age, total cholesterol, HDL cholesterol, SBP, smoking status, and evidence of 
diabetes were scored using the Framingham Heart Study General CVD 10-Year Risk multivariate risk 
factor algorithm (D’Agostino et al. 2008). 
Statistical Analysis 
Statistical analyses were performed using SAS software (Version 9.2; SAS Inc, Cary NC). Results 
with P values < 0.05 were considered statistically significant. Median (lower, upper quartile) values are 
presented for urinary analyte excretion (Table 2) and dietary intake (Table 4) data because these data 
were not normally distributed. To detect differences among the treatment groups at baseline and week 
8, urinary isoflavone excretion and urinary sodium and potassium data were analyzed using a 
nonparametric Kruskal-Wallis test. To determine differences in urinary isoflavone excretion at 8 weeks, 
we used a follow-up Tukey multiple comparison test. Mean (+95% confidence interval; minima and 
maxima) values for data on descriptive characteristics that approximated a normal distribution (age; 
height; weight; BMI; waist circumference; total cholesterol; LDL cholesterol; HDL cholesterol; 
triglycerides; serum glucose) are presented in Table 3. To detect differences among treatment groups at 
baseline, subject characteristics data were analyzed using an analysis of variance (ANOVA). Potential 
treatment effects on the response variables (serum sVCAM-1, sICAM-1, and sE-selectin) over time (Table 
5) were tested using repeated measures ANOVA, with the inclusion of gender as a covariate. Treatment 
effects were further analyzed with a multivariate analysis of variance (MANOVA), but this analysis did 
not alter the results (and hence these data are not reported). 
 
RESULTS 
Subject Characteristics and Dietary Intake 
We enrolled healthy prehypertensive/Stage 1 hypertensive men  and premenopausal women in 
a randomized Iowa Soybean Association-funded clinicalstudy. Among the 144 individuals who 
completed pre-baseline screening, 73 were eligible to participate in baseline testing, of which 72 met 
the criteria and were randomly assigned to treatment within the confines of tolerance to soy beverage 
treatment. A total of 68 participants (60 men and 8 women) completed the eight week trial. Baseline 
characteristics of all participants according to treatment are presented in Table 3. There were no 
statistically significant differences among treatment groups at baseline for these variables. Although 
participants ranged in age from 18 to 63 y, the majority were young adults, ages 26 to 32 y. Nearly all 
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participants were non-smokers, with the exception of one daily smoker in each treatment group. 
Overall, each treatment group was considered overweight based upon their mean BMI, whereas the 
study sample included 23 normal weight (BMI 18.5-24.9), 28 overweight (BMI 25.0-29.9), and 17 class I 
obese participants (BMI 30.0-34.9). Although the majority of participants had waist circumference 
measurements considered “normal-risk”, one female and eleven male participants exceeded the cutoff 
point (>88 cm for women, >102 cm for men) and were considered “high risk”. Resting and mean 24-hour 
blood pressure for the entire sample fell within the prehypertensive ranges, including those 45 
considered prehypertensive and 23 considered Stage I hypertensive. For each treatment beverage 
group, the mean value fell within the normal range for serum total cholesterol (<200 mg/dL), HDL 
cholesterol (>40 mg/dL), triglycerides (<150 mg/dL), and fasting glucose (<100 mg/dL); however, mean 
LDL cholesterol in the SPI beverage group (114 mg/dL) was slightly above the “optimal” cut-off (<100 
mg/dL). We observed SBP > 160 mmHg for one male participant who provided written permission from 
his physician to continue participation. We observed high total cholesterol for one male (289 mg/dL) 
and one female (298 mg/dL) participant who provided written permission from their physicians to 
continue participation. When parameters were scored to predict 10-year CVD risk, participants overall 
exemplified 4.3% risk of CVD at baseline (D’Agostino et al. 2008). 
Dietary intake data are presented in Table 4. Carbohydrate, protein, and fat consumption fell 
within recommended macronutrient distribution ranges for each treatment group. In comparison to 
established Dietary Reference Intakes (DRIs), participants consistently consumed excess sodium, 
whereas intakes of magnesium, potassium, copper, and zinc were below the DRIs. Vitamins A, D, and K 
were also below the DRIs across treatment groups, in addition to biotin and pantothenic acid. 
Urinary Analyte Excretion and Compliance 
 Urinary electrolyte and total urinary isoflavone excretion for each treatment group are 
presented in Table 2. Urinary sodium and potassium excretion were not significantly different among 
treatment groups at baseline or week 8. Urinary isoflavone excretion was higher in the soy beverage 
groups compared with the control group, thus reflecting adherence to treatment. Based upon the 
nonparametric Kruskal-Wallis test, we found significant differences in urinary isoflavone excretion 
among the three treatment groups at week 8, as well as between each treatment comparison (based 
upon follow-up Tukey multiple comparison test). Compliance indicated by leftover milk returned in half 
gallon milk cartons and subjective report reflected excellent treatment adherence, with 98% of 
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participants at least 90% compliant. However, these self reports are subjective and thus susceptible to 
participant reporting error. 
Serum Cell Adhesion Molecules 
Median (lower, upper quartile) serum concentrations of ICAM-1, VCAM-1, and E-selectin at 
baseline and week 8 are presented for each treatment group in Table 5. CAM concentrations were not 
consistently related to blood pressure, with the exception that E-selectin was significantly positively 
correlated to mean 24-hour SBP and DBP at baseline. ANOVA indicated that there was no time by 
treatment interaction (no treatment effect) or age effect, but there was a gender effect for ICAM-1 
(P=0.0037), whereas gender did not reach significance for E-selectin (P=0.067) or VCAM-1 (P=0.16). 
Given these results, gender was important to consider as a potentially confounding factor in the 
analysis, whereas removing women from the analysis (focusing on men only) did not alter the overall 
results. Men had higher circulating concentrations of ICAM-1 and E-selectin, respectively, at both 
baseline (P = 0.0071 and P = 0.049) and week 8 (P = 0.0054 and P = 0.038). 
 
DISCUSSION 
Daily intake of cow’s milk or soy beverages prepared from WSB or SPI for eight weeks did not 
significantly alter soluble CAM concentrations in prehypertensive/Stage I hypertensive individuals. 
Because CAM serve as biomarkers of atherosclerotic CVD, a reduction in CAM concentration in high-risk 
individuals, such as hypertensives, may reduce the risk of CVD and a dietary treatment may offer an 
alternative preventive measure in otherwise healthy early stage hypertensive individuals. Although 
previous clinical studies have examined the effect of dairy and soy product intake on CAM, this study 
was unique in that we included premenopausal women and men, whereas prior investigations examined 
postmenopausal women almost exclusively. Nonetheless, our results are in general agreement with 
previous findings. 
Our results were similar to those of Blum et al. (2003) who provided hypercholesterolemic 
postmenopausal women with 25 g of soy protein and protein placebo daily for 6 weeks using a 
crossover design, with a 1 month washout period. The soy protein did not affect sVCAM-1, sICAM-1, or 
sE-selectin in comparison with the placebo (Blum et al. 2003). Steinberg et al. (2003) enrolled 
postmenopausal women who consumed 25 g/d of 2 soy products (SPI with isoflavones [107 mg/d]; SPI 
with trace isoflavones [2 mg/d]); and total milk protein (no isoflavones) for 6 weeks each, with 4 week 
washout periods between treatments. No significant changes in CAM were observed among the three 
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dietary groups. In a similar study (Hall et al. 2005), postmenopausal women consumed isoflavone-
enriched (50 mg/d) or placebo cereal bars daily for eight weeks, with no change in CAM concentrations. 
However, one interesting note from these authors indicated that women in an estrogen receptor-β gene 
polymorphic subgroup exhibited some improvement in VCAM-1 (P < 0.05). Finally, postmenopausal 
women with a history of breast cancer were given isoflavone (114 mg) or placebo tablets daily for 3 
months with no treatment difference reported in sE-selectin concentration (Nikander et al. 2003). 
Although no significant change in E-selectin occurred, serum daidzein (r= 0.39; P < 0.003) and genistein 
(r= 0.38; P < 0.004) concentrations were inversely associated with E-selectin concentration (Nikander et 
al. 2003). 
Not all results are consistent with these reports or the findings of our study. Men and 
postmenopausal who were provided isoflavone tablets (80 mg/d total isoflavones) for six weeks 
experienced a significant reduction in sVCAM-1 (P = 0.009) (Teede et al. 2003). Nasca et al. (2008) 
supplemented healthy postmenopausal women with a therapeutic lifestyle change diet alone or a 
therapeutic lifestyles change diet which replaced 25 g of nonsoy protein with 0.5 cups of soy nuts (25 g 
soy protein, 101 mg total isoflavones) for 8 weeks. The women who consumed this diet daily did not 
experience significant reductions in sVCAM-1 or sICAM-1, with the exception of a reduction in sVCAM-1 
for hypertensive versus normotensive women who consumed the soy protein rich lifestyle change diet 
(Nasca et al. (2008). Whereas previous studies found significant positive correlations between SBP and 
sICAM-1 (r = 0.50, P = 0.02) (Chae et al. 2001), DBP and sICAM-1 (r = 0.49, P = 0.03), and SBP and 
sVCAM-1 (r = 0.43, P = 0.05) (DeSouza et al. 1997), our study did not replicate these results. E-selectin 
was significantly and positively correlated to baseline mean 24-hour SBP (r = 0.30, P = 0.013) and DBP (r 
= 0.30, P = 0.014), but not to in-house 10-minute resting blood pressure or to any blood pressure 
measure at week 8. 
In our study, treatment groups were provided two levels of dietary isoflavones (SPI:  30.1 mg/d; 
WSB:  91.4 mg/d) compared with no isoflavones from cow’s milk. The greatest amount of isoflavones 
consumed daily (WSB:  91.4 mg/d) was similar to amounts previously reported whereby beneficial 
effects were noted on CAM and other clinical risk factors of atherosclerotic CVD , such as elevated 
serum cholesterol (Zhan and Ho 2005) and blood pressure (He et al. 2005; Jenkins et al. 2002). Thus, lack 
of treatment effect in our study was not likely due to the isoflavone content of the beverages. 
The presence of soluble CAM in human sera has been implicated in atherosclerotic CVD, as CAM 
have been found locally in atherosclerotic plaques (Davies et al. 1993; O’Brien et al. 1996) and were 
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higher in circulation for individuals with atherosclerosis compared with healthy individuals (Hwang et al. 
1997; Peter et al. 1997). As markers of atherosclerosis, the biological relevance of the CAM 
concentrations observed in our participants (Table 5) may suggest that they had near normal risk of 
atherosclerotic CVD, although our participants had above normal blood pressure. In comparison to 
mean CAM concentrations in patients with incident coronary heart disease (CHD) (sICAM-1 = 288.7 
ng/mL; sE-selectin = 38.2 ng/mL) or coronary artery atherosclerosis (CAA) (sICAM-1 = 283.6 ng/mL; sE-
selectin = 41.5 ng/mL), our participants had CAM concentrations (Table 5) at or below the values 
observed for healthy controls or the reference group (sICAM-1 = 244.2 ng/mL; sE-selectin = 32.8 ng/mL) 
(Hwang et al. 1997). Note that the median (lower, upper quartile) values presented for our data (they 
were not normally distributed) may not be entirely comparable with published mean values. Because 
the mean values for each marker were slightly higher than the corresponding median values in our 
participants, this suggested that our mean values were comparable to published mean values. Based 
upon these findings, our participants were likely at greater risk of atherosclerotic CVD primarily because 
of their prehypertensive/hypertensive state. However, we cannot suggest from our results that the CAM 
concentrations we observed placed our participants at overall high risk of CVD. Further, although mean 
Framingham 10-year CVD risk score was 4.3%, in comparison to Framingham risk scores standardized for 
age and gender (Wilson et al. 1998), our participants on average exhibited risk accounting for only 90% 
of their expected average risk. To standardize these risk scores, each score was divided by the average 
expected score for that particular individual based on age and gender. This low risk is attributed to our 
sample primarily being relatively young adults and overall lacking in other risk factors, such as diabetes 
or hypercholesterolemia. Our participants were individuals with early stage HTN who were otherwise 
healthy. 
Our inability to demonstrate a treatment effect on CAM was initially suspected to be explained 
by baseline CAM concentrations that were similar to normotensive individuals and hence within the 
expected range for healthy individuals. In comparison to mean CAM concentrations (ng/mL) reported by 
DeSouza et al. (1997) for hypertensive (sICAM-1 = 232.4 ± 16.5; sVCAM-1 = 737.3 ± 65.6) and 
normotensive (sICAM-1 = 189.8 ± 11.2; sVCAM-1 = 565.7 ± 4/6.8) individuals, concentrations observed in 
our participants (Table 5) were comparable. The majority of our hypertensive and prehypertensive 
individuals were young, otherwise healthy adults, which may account for the lower CAM concentrations 
compared to reported values for hypertensive individuals in other studies. Further, when examined 
separately at baseline, no significant differences in CAM concentrations were noted between 
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hypertensive and prehypertensive participants. It is important to note that although participants in the 
present study had elevated blood pressure, mean blood pressure for this group (resting or mean 24-
hour) fell within the prehypertensive range. Whereas baseline CAM concentrations appeared similar to 
normotensive individuals, previous reports have indicated a significant reduction in CAM with isoflavone 
supplementation despite baseline concentrations being much lower (Atteritano et al. 2007) than those 
observed in our participants. Also, studies that reported significant reductions typically enrolled three to 
four times the number of participants in comparison to the present study. Therefore, it may not be 
appropriate to attribute the lack of treatment effect to relatively low baseline CAM concentrations, but 
rather to the relatively small sample size given the large variability in these markers. 
Despite being prehypertensive, our participant CAM concentrations reflected that of 
normotensive individuals, raising speculation as to whether a blood pressure threshold must be reached 
to raise CAM concentrations. Such a threshold has yet to be identified. We also found no correlation 
between blood pressure and CAM, with the exception of E-selectin and baseline 24-hour blood pressure 
measures. Further work in this area, examining a wider range of blood pressures, would be necessary to 
identify a blood pressure threshold above which CAM concentrations are elevated. Likewise, clinical 
reference ranges indicative of low or high CAM concentrations do not yet exist; these values would be 
very useful in the intrepretation of results. Although significant time effects were observed for sE-
selectin and sVCAM-1 (+4.2% and -8.5%, respectively), these changes may not be large enough to be 
biologically important. Also, if these markers were truly indicative of ‘normal’ risk at baseline, a 
reduction in any marker would not necessarily lessen the risk. The positive change in sE-selectin 
observed at week 8, albeit significant, was an increase of only 1.6 ng/mL, and did not reach the 
concentration observed in patients with CVD. Considering that the CAM concentrations in our 
participants likely indicated ‘normal’ risk, we should not expect a similar magnitude of response to 
treatment with individuals who have higher baseline CAM concentrations. It is also important to 
mention the great inter- and intra-individual variability in these biomarkers, contributing to difficulty in 
demonstrating statistical significance.These points illustrate that one must have available clinical 
reference ranges to interpret the biological importance of changes in these CAM biomarkers. 
The present study is limited in that participants were enrolled based upon blood pressure 
inclusion criteria, without knowledge of their CAM concentrations prior to baseline. Because our 
participants did not exhibit elevated CAM concentrations at baseline, this may have restricted our ability 
to demonstrate a treatment effect or change over time. Also, we did not recruit normotensive 
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individuals to serve as the control group, thereby limiting our ability to compare CAM concentrations in 
an at-risk group to those with ‘normal’ risk. Including normotensive individuals may have provided 
further insight as to whether our prehypertensive/Stage 1 hypertensive participants should be 
considered at-risk based upon their CAM values. In addition, enrolling an equal number of Stage I 
hypertensive versus prehypertensive participants may have more clearly demonstrated the relationship 
between CAM concentrations and blood pressure. However, we enrolled 23 hypertensive versus 45 
prehypertensive participants in the present study. It may be possible that we included participants who 
were not truly hypertensive throughout the study because we based their classification on prescreening 
blood pressure measures that may have been higher than their typical or subsequent blood pressure. 
Hence, the mean blood pressure for our participants reflected mainly the prehypertensive category, 
perhaps partially accounting for the undetectable treatment effect. In addition to these limitations, our 
sample size was relatively small given the large variability in these markers. The Framingham risk score 
calculations are primarily designed for individuals who are ages 30-74, however participants in this study 
ranged from ages 18-63. These calculations require age 30 to be used in place of any age less than 30, 
thus these results may not accurately reflect CVD risk for individuals less than 30 years of age.  
Our study design did not include a true control group. Although we did not expect the same 
magnitude of response from the cow’s milk group, all participants received a treatment beverage. Thus, 
we were unable to compare change in CAM concentrations to individuals without any treatment, which 
is exceedingly difficult in dietary intervention studies. In addition, we did not incorporate a washout 
period before participants began receiving treatment. Although the soy food intake questionnaire and 
baseline urinary isoflavone excretion data indicated that the vast majority of the participants did not 
consume appreciable amounts of soy products, there was a range of soy intake prior to starting 
treatment. It is possible, although not probable, that this may have contributed to the lack of treatment 
effect. Finally, the enrollment of a far greater number of men (n=60) than women (n=8) made 
interpretation of a gender effect difficult, and because previous research in this area included primarily 
postmenopausal women, we did not have comparable values for men or premenopausal women from 
the literature. It proved exceedingly difficult to recruit premenopausal women who were hypertensive 
who also had a BMI < 35. Nevertheless, we demonstrated that gender was an important factor to 
consider in the analysis. 
Despite these noted limitations, the strength of this study was the inclusion of healthy 
individuals with isolated prehypertension or Stage 1 hypertension at relatively low risk of CVD. Hence, 
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one interpretation might be that dietary intervention does not measurably improve CAM in early stage 
hypertensive but otherwise healthy individuals. Perhaps decreasing CAM concentrations may not be the 
mechanism by which soy protein with isoflavones might reduce the risk of CVD in early stage 
hypertensive individauls. Perhaps isoflavone treatment may be more beneficial to individuals exhibiting 
a myriad of CVD risk factors, but our study was not designed to test this hypothesis. Our study was also 
unique in that it included premenopausal women, thus making a contribution in CAM values to the 
literature. It is well established that postmenopausal women are at increased risk of CVD compared to 
their premenopausal counterparts. However, the progression of atherosclerosis occurs over the entire 
life span. Thus, ameliorating the progression of atherosclerosis in younger years should favorably impact 
atherosclerotic CVD risk later in life. Enrolling prehypertensives, in addition to early stage hypertensives, 
was intended to allow the comparison of CAM concentrations between these blood pressure groups. 
However, for reasons provided above, we did not find significant differences between the 
prehypertensive and hypertensive participants. 
In conclusion, prehypertensive/Stage I hypertensive individuals who consumed either cow’s milk 
or soy beverages (prepared from WSB or SPI) for 8 weeks daily did not show any change in soluble CAM 
concentrations. Consequently, we cannot suggest that daily intake of either cow’s milk or soy protein 
beverages improves circulating CAM concentrations and hence risk of atherosclerotic CVD in similar 
individuals. Further, as had been reported in some groups of hypertensive individuals, our data 
suggested that CAM concentrations were not elevated at baseline in potentially at-risk prehypertensive 
individuals. 
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TABLES 
Table 1. Nutrient composition of treatment beverages 
  Cowa SPIb WSBc 
Serving size 240 mL (1 cup) 240 mL (1 cup) 240 mL (1 cup) 
Energy (kcal) 100 100 100 
Protein (g) 8 6 6.25 
Total Fat (g) 2.5 3 3.5 
Saturated fat (g) 1.5 0.5 0.5 
Trans fat (g) 0 0 0 
Polyunsaturated fat (g) - - 2 
Monounsaturated fat (g) - - 1 
Cholesterol (mg) 15 0 0 
Total Carbohydrates (g) 13 11 10 
Fiber (g) 0 0 1 
Sugars (g) 13 10 7 
Sodium (mg) 125 105 95 
Potassium (mg) 410 - 300 
Phosphorus (mg) - - - 
Magnesium (mg) - - 40 
Zinc (mg) - 2.25 1.5 
Calcium (mg) 300 300 300 
Iron (mg) - 1.1 1.1 
Selenium (μg) - - 5.6 
Vitamin A (IU) 500 500 500 
Vitamin C (mg) 2.4 - - 
Vitamin D (IU) 100 100 120 
Riboflavin (mg) - - 0.5 
Folate (μg) - - 24 
Vitamin B12 (μg) - 1.5 3 
Total Isoflavones (mg) - 8.6 26.1 
Genistein (mg)  - 5.1 16.1 
Daidzein (mg)  - 2.3 8.8 
Glycitein (mg)  - 1.2 1.2 
a 
Cow: Cow's milk beverage    
b 
SPI: Soy beverage prepared from soy protein isolate   
c 
WSB: Soy beverage prepared from whole soy bean   
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Table 2. Urinary analyte excretion 
  Treatment Beverage Group   
  Cowa (n= 21 ) SPIb (n= 23) WSBc (n= 24)   
Total Urinary Isoflavone (µmol/L) Median (lower, upper quartile values) P value 
Baseline 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.53 
Week 8 0.5 (0.0, 2.4) 6.7 (3.7, 11.7) 17.6 (7.1, 28.0) <0.001d 
Urinary sodium (mmol/day)        
Baseline 197 (156, 235) 193 (142, 243) 180 (148, 211) 0.75 
Week 8 135 (104, 167) 131 (91, 190) 146 (109, 191) 0.61 
Urinary potassium        
Baseline 65 (47, 84) 67 (49, 84) 60 (50, 69) 0.98 
Week 8 54 (45, 80) 45 (28, 73) 69 (47, 90) 0.12 
Median (lower, upper quartile values) 
a 
Cow:  Cow's milk beverage 
b 
SPI:  Soy beverage prepared from soy protein isolate 
c  
WSB:  Soy beverage prepared from whole soy bean 
d 
Significant differences among treatment beverage groups using Kruskal-Wallis (P < 0.05) 
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Table 3. Characteristics of participants at baseline 
  Treatment Beverage Group       
Characteristic Cowa (n= 21 )   SPIb (n= 23)   WSBc (n= 24)   All (N = 68) 
  Mean (95% CI)    Mean (95% CI)  
  (min,max)   (min,max) 
Age (years) 30 (26, 32)   29 (24, 34)   29 (24, 34)   29 (26, 32) 
  (19, 63)   (19, 63)   (18, 53)   (18, 63) 
Gender (n [%])                       
Male 21 (100%)   20 (87%)   19 (79%)   60 (88%) 
                                           Female 0   3   5   8 
Race/Ethnicity (n [%])                       
White 18 (85.7%)   16 (69.6%)   19 (79.2%)   53 (77.9)% 
Asian 1 (4.8%)   6 (26.1%)   4 (16.7%)   11 (16.2%) 
Black 1 (4.8%)   0   1 (4.2%)   2 (2.9%) 
Hispanic 1 (4.8%)   1 (4.3%)   0   2 (2.9%) 
Height (cm) 179.4 (173.8, 184.9)   175.7 (170.8, 180.7)   178.6 (172.2, 182.9)   177.8 (175.1, 180.6) 
  (132.3, 193.9)   (147.5, 197.2)   (149.4, 193.9)   (132.3, 197.2) 
Males 179.4 (173.8, 184.9)   179.6 (175.8, 183.4)   181.3 (178.2, 184.4)   180.1 (177.6, 182.6) 
Females - -   161.8 (153.5, 170.1)   159.4 151.2, 167.7)   160.9 (154.4, 167.4) 
Weight (kg) 88.7 (81.4, 96.1)   84.5 (77.2, 91.9)   88 (81.5, 94.5)   87 (83.2, 90.9) 
  (63.9, 122.8)   (57.8, 128.2)   (56.6, 115.5)   (56.6, 128.2) 
Males 88.7 (81.8, 95.6)   88.6 (81.4, 95.9)   91.6 (86.1, 97.1)   89.7 (85.9, 93.4) 
Females - -   69.7 (59.1, 80.4)   63.1 (57.5, 68.9)   67.3 (59.4, 75.1) 
BMI (kg/m2) 26.7  (24.6, 28.7)   27.1 (25.2, 29.0)   27.3 (25.8, 28.7)   27.0 (26.0, 28.0) 
  (20, 36)   (21, 35)   (21, 32)   (20, 36) 
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Table 3. (Continued) 
Characteristic Cowa (n= 21 )   SPIb (n= 23)   WSBc (n= 24)   All (N = 68) 
Waist circumference (cm) 91.4 (84.5, 98.4)   89.7 (84.5, 95.0)   91.5 (86.6, 96.3)   90.9 (87.8, 94.0) 
  (72.5, 126.0)   (72.5, 115.0)   (72.6, 117.1)   (72.5, 126.0) 
Males 91.4 (84.5, 98.4)   92.6 (89.3, 98.2)   93.7 (87.2, 98.0)   92.6 (89.5, 95.7) 
Females - -   75.7 (70.0, 81.3)   79.3 (69.2, 86.5)   78.0 (78.0, 82.8) 
Smoking status (n)                       
Non-smoker 17   22   23   26 
Recently quit 1   0   0   1 
1-2 times/month 1   0   0   1 
1-2 times/week 1   0   0   1 
Daily 1   1   1   3 
Resting BP (mmHg)                       
SBP 132  (129, 135)   133  (130, 136)   136  (132, 140)   134  (132, 136) 
  (120, 143)   (120, 143)   (118, 155)   (118, 155) 
DBP 79  (75, 84)   84  (81, 88)   86  (81, 90)   83  (81, 86) 
  (63, 100)   (70, 98)   (67, 123)   (63, 123) 
Mean 24 hr ambulatory BP (mmHg)                     
SBP 136 (131, 140)   134 (129, 138)   136 (133, 140)   135 (133, 138) 
  (120, 157)   (118, 167)   (117, 151)   (117, 167) 
DBP 77 (73, 81)   78 (74, 81)   78 (74, 81)   78 (73, 81) 
  (67, 99)   (68, 100)   (63, 94)   (67, 100) 
Serum total cholesterol (mg/dL)d 168 (154, 182)   185 (167, 203)   172 (156, 188)   175 (166, 184) 
  (133, 249)   (130, 289)   (119, 298)   (119, 298) 
Serum LDL (mg/dL)d 98 (85, 111)   114 (100, 128)   100 (86, 113)   104 (96, 112) 
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Table 3. (Continued) 
Characteristic Cowa (n= 21 )   SPIb (n= 23)   WSBc (n= 24)   All (N = 68) 
  (56, 169)   (65, 177)   (60, 214)   (56, 214) 
Serum HDL (mg/dL)d 45 (41, 49)   47 (42, 51)   44 (40, 48)   45 (43, 48) 
  (31, 58)   (29, 73)   (28, 73)   (28, 73) 
Serum triglycerides (mg/dL)d 127 (94, 159)   124 (89, 159)   140 (110, 170)   130 (112, 149) 
  (43, 282)   (44, 328)   (49, 285)   (43, 328) 
Fasting glucose (mg/dL)d 85 (82, 89)   89 (84, 93)   88 (85, 91)   87.4 (85, 89) 
  (76, 113)   (73, 121)   (76, 111)   (73, 121) 
Metabolic syndrome scored 1.4 (0.9, 1.9)   1.5 (1.1, 2.0)   1.6 (1.2, 2.0)   1.5 (1.3, 1.7) 
  (0, 3)   (0, 3)   (0, 3)   (0, 3) 
Urinary sodium (mmol/d) 197 (156, 235)   193 (142, 243)   180 (148, 211)   189 (167, 212) 
 (85, 430)   (25, 498)   (75, 359)   (25, 498) 
Urinary potassium (mmol/d) 65 (47, 84)   67  (49, 84)   60 (50, 69)   64 (56, 72) 
  (22, 215)   (23, 191)   (21, 104)   (21, 215) 
Mean (95% CI) (min,max) 
BP: Blood pressure; LDL: Low-density lipoprotein; HDL: High-density lipoprotein       
a 
Cow:  Cow's milk beverage 
b 
SPI:  Soy beverage prepared from soy protein isolate 
c 
WSB:  Soy beverage prepared from whole soy bean 
d 
One data point missing from SPI treatment beverage group 
e 
Metabolic syndrom score based on American Heart Association/Updated NCEP guidelines:  waist circumference:  men ≥ 102 cm, women ≥ 88 
cm; triglycerides ≥ 150; HDL men < 40, women < 50; SBP ≥ 130 and/or DBP ≥ 85; fasting glucose ≥ 100 
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Table 4. Energy and nutrient intake at baseline 
  Treatment Beverage Group       
Nutrient Cowa (n= 21 )   SPIb (n= 23)   WSBc (n= 24)   All (N = 68) 
  Median (lower, upper quantile values)   
Energy (kcal) 2675 (2362, 3038)   2300 (1887, 2898)   2869 (2286, 3121)   2614 (2106, 3042) 
Protein (g) 92.4 (74.7, 128.0)   91.7 (71.9, 138.9)   102.9 (80.1, 135.4)   95.3 (75.3, 133.2) 
Total Fat (g) 96.3 (77.0, 105.7)   85.2 (51.6, 119.7)   97.0 (78.6, 119.6)   92.1 (66.4, 115.7) 
Saturated (g) 32.5 (20.5, 40.2)   25.3 (16.8, 44.1)   31.0 (26.8, 42.3)   30.9 (21.9, 41.2) 
Monounsaturated (g) 23.8 (20.4, 32.3)   19.8 (13.5, 35.5)   22.6 (16.7, 34.9)   23.0 (16.7, 33.5) 
Polyunsaturated (g) 12.7 (8.1, 15.8)   10.6 (7.0, 16.4)   11.0 (7.1, 16.9)   11.7 (7.2, 16.5) 
Trans (g) 0.5 (0.1, 1.9)   0.4 (0.0, 1.3)   1.0 (0.4, 2.1)   0.7 (0.1, 1.8) 
Carbohydrates (g) 315 (259, 388)   282 (200, 311)   322 (286, 357)   311 (246, 370) 
Dietary Fiber (g) 16.3 (11.7, 23.5)   17.7 (12.0, 26.1)   16.3 (11.5, 27.5)   17.0 (11.7, 24.8) 
Calcium (mg) 1010 (811, 1566)   885 (523, 1366)   1198 (879, 1529)   1028 (672, 1495) 
Phosphorus (mg) 1245 (853, 1593)   1092 (665, 1979)   1247 (1027,1793)   1230 (848, 1700) 
Magnesium (mg) 252 (220, 338)   189 (117, 389)   273 (204, 383)   250 (160, 360) 
Sodium (mg) 3646 (3417, 4810)   3764 (2593, 4939)   4225 (3570, 5073)   3930 (2986, 4914) 
Potassium (mg) 2642 (1910, 3068)   1914 (1432, 3637)   2526 (1658, 3399)   1628 (2377, 3308) 
Iron (mg) 17.2 (13.2, 26.5)   16.8 (9.6, 27.1)   21.3 (13.9, 28.7)   18.2 (12.0, 27.3) 
Zinc (mg) 13.7 (11.6, 18.8)   8.7 (5.4, 20.4)   12.7 (8.4, 22.3)   13.3 (8.1, 2.1) 
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Table 4. (Continued) 
Nutrient Cowa (n= 21 )   SPIb (n= 23)   WSBc (n= 24)   All (N = 68) 
Copper (mg) 1.2 (0.9, 1.5)   1.1 (0.5, 1.9)   1.3 (0.9, 2.0)   1.2 (0.8, 2.0) 
Vitamin A (IU) 4477 (2925, 7121)   5564 (2199, 8870)   6390 (3760, 9152)   5038 (2515, 8208) 
Vitamin D (IU) 229 (113, 395)   192 (61, 667)   108 (15, 418)   165 (5, 426) 
Vitamin E (IU) 3.2 (1.3, 12.4)   3.4 (0.1, 32.0)   2.9 (0.8, 32.7)   3.3 (0.6, 31.3)  
Vitamin K (µg)  31 (21, 53)   44 (25, 110)   50 (32, 80)   40 (23, 75) 
Vitamin C (mg) 58 (41, 120)   94 (47, 168)   102 (43, 180)   94 (42, 153) 
Vitamin B1 (mg) 1.8 (1.6, 2.2)   1.9 (1.0, 3.0)   1.6 (1.2, 3.1)   1.9 (1.1, 3.0) 
Vitamin B2 (mg) 2.5 (2.1, 2.8)   2.2 (1.2, 3.7)   2.3 (1.5, 4.2)   2.4 (1.5, 3.7) 
Vitamin B3 (mg) 26.2 (19.6, 33.4)   27.3 (13.8, 47.3)   26.3 (18.4, 45.5)   26.4 (16.9, 40.7) 
Pantothenic acid (mg) 5.3 (4.2, 7.1)   4.6 (2.9, 12.2)   4.9 (2.8, 12.7)   4.9 (2.9, 11.5) 
Vitamin B6 (mg) 2.1 (1.4, 2.4)   1.9 (0.8, 4.5)   2.1 (1.2, 4.3)   2.1 (1.1, 3.5) 
Biotin (µg)  18.3 (12.6, 27.1)   20.0 (5.7, 40.5)   16.1 (4.3, 47.5)   19.1 (6.4, 38.5) 
Vitamin B12 (µg)  6.6 (4.8, 9.6)   6.3 (2.9, 9.4)   7.4 (3.1, 13.4)   6.5 (3.6, 12.0) 
Alcohol (g) 27.3 (0.0, 47.4)   0.0 (0.0, 3.0)   5.6 (0.0, 33.5)   2.5 (0.0, 36.5) 
Median (lower, upper quantile values) 
Determined from 3-day food diaries recorded at baseline 
a 
Cow: Cow's milk beverage           
b 
SPI: Soy beverage prepared from soy protein isolate         
c 
WSB: Soy beverage prepared from whole soy bean          
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Table 5. Soluble endothelial adhesion molecules at baseline and after 8 weeks of treatment beverage intake 
  Treatment Beverage Group ANOVA (P value) 
  Cowa (n= 21 ) SPIb (n= 23) WSBc (n= 24) Time*Treatment Gender 
I-CAM-1 (ng/mL)       
Baseline 214.8 (135.5, 268.9) 184.5 (151.0, 223.4) 179.7 (142.8, 214.7) 0.32 0.0037 
Week 8 192.8 (141.4, 239.9) 201.4 (148.6, 231.2) 187.9 (131.2, 233.1)     
Change -10%   9%   5%       
VCAM-1  (ng/mL)                 
Baseline 480.3 (431.1, 625.9) 488.8 (326.4, 560.8) 506.7 (443.9, 554.4) 0.85 0.16 
Week 8 463.5 (423.0, 535.7) 389.9 (352.7, 481.8) 474.7 (347.9, 589.1)     
Change -3%   -20%   -6%       
E-selectin  (ng/mL)                 
Baseline 37.2 (32.3, 50.0) 36.4  (29.2, 49.8) 38.1 (28.0, 47.6) 0.23 0.067 
Week 8 37.4 (31.5, 52.2) 36.8 (31.0, 47.2) 43.7 (32.2, 54.6)     
Change 1%   1%   14%       
Median (lower, upper quartile values) 
a 
Cow: Cow's milk beverage 
b 
SPI: Soy beverage prepared from soy protein isolate 
c 
WSB: Soy beverage prepared from whole soy bean 
I-CAM-1: Intercellular adhesion molecule 1; VCAM-1: Vascular cell adhesion molecule 1; E-selectin: Endothelial leukocyte adhesion molecule 1  
ANOVA indicated no time*treatment interaction, but gender effect for I-CAM-1  
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GENERAL CONLCUSIONS 
In summary, results for the primary objective of this study indicated that daily consumption of 
cow’s milk or soy protein beverage prepared from SPI or WSB did not alter sCAM concentrations in 
prehypertensive/Stage I hypertensive men and premenopausal women. Consequently, we cannot 
suggest that daily intake of either cow’s milk or soy protein beverages will improve circulating sCAM 
concentrations and hence lessen the risk of atherosclerotic CVD in premenopausal women or men. 
Further, these data suggested that sCAM at baseline in prehypertensive individuals were not elevated to 
potentially at-risk concentrations, as has been reported in hypertensive individuals. Results pertaining to 
our secondary objective suggested a gender difference for ICAM-1 and E-selectin (statistical trend) in 
prehypertensive individuals, demonstrated by significantly greater concentrations observed for men at 
baseline and week 8. 
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